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CHAPTER I 
INTRODUCTION 
Cancer is often a fatal disease as well as a debilitating condition 
that is estimated to be responsible for one out of five deaths in the United 
States alone 1. Since there is no cure for cancer. patients must undergo 
a series of radiation treatments and other chemotherapies that target the 
tumor cells but are unfa1unately not specific for diseased tissue. The 
resulting side effects that patients experience due to existing treatments, 
can compromise the quality of life of the patient. Therefore it is highly 
desirable to find chemotherapies that specifically attack cancer cells 
while limiting side effects by imparting minimal destruction of healthy 
tissue. 
One chemotherapy that offers promise as a selective yet effective 
method for tumor eradication is photodynamic therapy (PDT) 8-
26,29,32,33,38, 44. The use of PDT as a chemotherapy requires that a 
photosensitizer be positioned within a target tissue, (either taken up 
selectively by tumor cells or placed in the tumor directly), while a directed 
light source irradiates the target tissue in the presence of oxygen. In 
order to be highly effective, the photosensitizer is distinguished by having 
a large quantum yield while absorbing in that spectral region where 
tissue transmits best, i.e., 650-900 nm. A compromise between 
2 
photosensitizer activation and tissue penetration is one of the key factors 
for success of PDT as a clinically viable treatment for cancers. Since 
many photosensitizers are also dyes, a factor that can compromise the 
use of dye mediated PDT is the phenomenon of aggregation 30,31,66_ 
The formation of dye molecule aggregates in aqueous solution can 
cause substantial deviations of Beer's law thereby modifying the 
absorption spectrum of the dye. This modification of the absorption 
spectrum of the dye, due to aggregation, could adversely affect its ability 
to act as a photosensitizer. The forces that control the degree of 
aggregation include structure of the dye, solvent, presence of OH 
functionality in the solvent, the reaction temperature, and the presence or 
absence of electrolytes. The phenomenon of aggregation and its effect 
on absorption parameters have been studied in many dye families 31. 
Included in the study were Rhodamine 6G and B, Fluorescein and 
Halofluorescein, Eosin, Erythrosin, Phloxin, and Rose Bengal. The 
general trends revealed by the study suggested that in aqueous solution, 
hydrogen bonding is the predominant force producing aggregation. In 
most of the dyes studied, a combination of forces controlled the degree of 
aggregation. 
The use of light absorbing chemicals to induce photoreactions 
was observed by Raab in 1900 2. He found that when paramecium were 
exposed to an Acridine dye derivative and light, the organisms began to 
die. In 1924, Policad observed that certain malignant tumors in animals 
3 
and man assumed a red color and fluoreced when exposed to light. This 
was attributed to the accumulation of endogenous porphyrins from a 
secondary infection of hemolytic bacteria 1 o. Finally, in 1961, Lipson 
and colleagues used a derivative of porphyrin, Hematoporphyrin 
derivative (Hpd) experimentally to treat a large, ulcerating recurrent 
breast tumor 3_ Hpd was shown to be therapeutic in the treatment of this 
tumor. Since 1961, many other investigators have used PDT as a 
therapeutic treatment for tumor destruction 9-12, 14-26. 
There are at least three different classes of photosensitizers that 
are currently being used for PDT. The most well known of all of these is 
Hematoporphyrin derivative (Hpd). Hpd was first synthesized in 1961 by 
researchers at the Mayo clinic as a probe for tumor detection 3, 12. Hpd 
is now known to be a mixture of porphyrins made up of hematoporphyrin 
(20%), its monohydration product, hydroxyethylvinyldeuteroporphyrin 
(25%), and the di-dehydration product protoporphyrin (5%). The rest of 
the mixture contained other porphyrins that were linked via ester and/or 
ether linkages. Some of the components of the Hpd were found to be 
inactive 1n viva An attempt was made to enrich the Hpd mixture with at 
least 80% of the active components. The resulting mixture, Photofrin 11 
(DHE) is currently undergoing phase Ill clinical trials 14, 17, 19-25,29. 
Porphyrins, (Figure 1 ), are thought to act via a energy-transfer process 
from the triplet state of the sensitizer to oxygen, producing singlet oxygen, 
(Type II reaction), which causes irreversible oxidation of some essential 
4 
cellular components and/or collapse of the tumor vasculature. The 
problem with this class of ctugs stems from the persistence of the ctug in 
actively dividing tissues such as the skin. Patients being treated with 
DHE are asked to avoid bright light for 30 days or more to avoid a severe 
sunburn reaction. 
The cyanines appear to be another medicinally useful class of 
photosensitizers. The Kryptocyanines (Figure 2) have been found to be 
particularly useful in PDT because of their high selectivity for 
incorporation into tumors and their strong absorption in the near IR 
region of the spectrum (706 nm) 46. Since the triplet state formation for 
Kryptocyanine is extremely inefficient, it is likely that the mode of action in 
the tumor cell is different than that of the porphyrins. It has been 
postulated that this class of dyes may act as a membrane disrupter either 
by binding specifically to the mitochondrial membrane and 
photoisomerizing it or causing non-specific cleavages in it when exposed 
to light. 
5 
COOH(CH2)2 
NH 
OH 
Fig. 1. 
6 
Fig. 2. 
Merocyanine (MC 540) is another cyanin derivative that has 
a very interesting profile. Investigators found that when MC 540 
(Figure 3) was exposed to light prior to its use in biological systems 
(preactivated), the pMC 540 was found to be composed of an undefined 
mixture of unique compounds that no longer required the presence of 
light exposure to elicit a PDT response in the clinical trials 13.45. Singlet 
oxygen generation was low but there was a rapid reaction between 
gound state MC 540 and singlet oxygen. In the presence of pMC 540, 
catalase and mannitol decreased dye potency. This and other data 
suggests that OH radical and 02- may be involved in the biological 
activity at the cell or mitochoncrial membrane. As with the porphyrins, 
skin sensitization lasts long after the initial treatment . 
....,__ _ o 
facH-CH=CH-CH 
N 
I 
(Cli!)~ OJNa 
Fig. 3. 
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The third class of photosensitizers can be characterized by 
belonging to the benzophenoxazine and benzophenthiazine family of 
dyes. In the late 1940's, Lewis and co-workers demonstrated that the 
benzophenoxazine family of dyes possessed many of the properties that 
characterize a potential photoactive drug 32,33. These lipophilic, 
cationic dyes have low systemic toxicity, are stable to physiological 
conditions, selectively stain tumors, and absorb light in the 600-660 nm 
range 51, 5 5, 56, 61 . However, this class of dyes were well known to be 
inefficient at forming triplet states. In 1987, Cincotta and Foley undertook 
the task of systematically examining the structural changes that would 
enhance triplet state formation in the excited state of this class of 
dyes 63-65. The study focused on several different parameters: the 
heavy atom effect, partition coefficients as a function of lipophilicity, 
absolute quantum yields of singlet oxygen generation as a function of 
triplet state lifetimes and the uptake and light/dark survival of the EMT-6 
8 
murine mammary sarcoma cell line 65. The protocols for these assays 
are covered elsewhere and are presumed to be standard assays for the 
art. As a result of these studies, the Cincotta goup concluded the 
following correlations between molecular and environmental changes 
and triplet state lifetimes. They found that substituting a S for 0 in the 
ring system increased the spin orbital coupling thereby enhancing triplet 
state conversion. Likewise, addition of a halide into the 
benzophenoxazine ring gave a similar response. Aggregation and 
increased hydrophobicity tended to decrease the triplet state lifetime 
while addition of an exocyclic ring, enhanced the triplet state lifetime 
66,67,76. The twisted intramolecular charge transfer model (TICT) was 
evoked to account for an abbreviated S1 lifetime thereby lowering 
intersystem crossing and triplet state formation. pH was found to be a 
critical factor in the formation of the triplet state because each tautomer 
has its own physicochemical properties including triplet lifetimes. 
Charge delocalized compounds tended to have geater triplet state 
lifetimes. Using this data as well as the measured absolute quantum 
yields of singlet oxygen, partition coefficients and 1n vitro data, the 
Cincotta-Foley group characterized the methylene blue derivatives of 
benzophenthiazine.as being ineffective photosensitizers 68-70. The 
methylene blue derivatives (Figure 5), in particular the iodine derivative 
of Azure A (Figure 4), showed a low partition coefficient but a large 
quantum yield for singlet oxygen generation. 
9 
Curiously, the in vitro data suggested that the compounds 
were absorbed into the cells but after exposure to dark and then light, 
nearly all of the cells survived. The group explained this result in terms of 
aggregation, internal bleaching, as well as unfavorable rates of efflux of 
the dye during the irradiation step. In addition, methylene blue has been 
shown to participate in type I photoreactions where the triplet state 
interacts directly with the biomolecule via hydrogen abstraction or 
electron transfer. The type 2 reaction results in energy being transfered 
to oxygen resulting in the singlet oxygen electrophile. Ito 74 suggested 
in a study published in 1983 that photosensitizers that participate in the 
type 1 reaction may not be effective on the membrane. 
N~ ~ 
+ + 
H3N s N(C 1i)2 Cl- er 
Fig. 4. 
As a result of these findings, the Foley, Cincotta group narrowed their 
research efforts to include only the commonly known Nile Blue and Nile 
Green derivatives of benzophenoxazine and benzophenthiazine 
(Figure 6). In 1990, a US patent was filed by these investigators 
claiming this series of derivatives as a novel photo-induced therapy for 
the killing of cancer cells 69. 
1 0 
Recently, there has been a renewed interest in examining the 
methylene blue family as potential photosensitizers for PDT. The 
compounds all absorb in the "therapeutic window" as well as having 
large molar extinction coefficients in this range. Since two of the major 
problems of the therapeutic use of these photosensitizers could include 
delivery of these dyes to the affected region and dye efflux, structural 
specificity could be built on to the dye via a linker and a receptor specific 
peptide chain. This would ensure delivery of the photosensitizer to the 
appropriate site while binding it to the site during irradiation. 
Calcitonin is a peptide hormone consisting of 32 amino acid 
residues linked by a 1-7 disulfide bridge 110,111,118,121,124,125. In 
mammals, the hormone originates in the thyroid gland, (calcitonin in 
mammals is usually referred to as thyrocalcitonin), and in submammalian 
vertebrates in the ultimobranchial body. Since its discovery and isolation 
in 1961 by Copp and co-workers, 123 the amino acid sequence of 
calcitonin in many animal species, has been described 110, 111. In most 
species, the hormone functions by inhibiting bone resorption. Calcitonin 
also promotes urinary clearance of calcium and phosphate. After 
investigating SAR relationships in these species, it has been found that 
S (CH3)2 
METHYLENE BLUECf 
s 
AZURE A 
s 
AZURE B 
s 
AZURE C 
s 
THIONIN 
Fig. 5. 
Cf 
Cf 
Cf 
Cl 
+ 
1 1 
l 2 
( +) 
x 
X= 0, S, Se 
Fig. 6. 
the amino acid sequence in residues 1-9 has been closely conserved. 
Variability in the amino acid sequence occurs in the middle of the chain. 
Calcitonin requires the complete 32 amino acid residue sequence for 
activity to be expressed; a loss of as little as the terminal amide 9"0UP 
can cause loss of biological activity 124_ 
The activity of calcitonin in human beings can be described as 
paradoxical. The importance of calcitonin seems to be expressed most 
consistently in regulating the calcium metabolism in young animals, 
especially in the embryonic stage of development. In adult humans. it is 
unknown whether calcitonin has any important physiological function. 
This can be exemplified in many case studies of adults that have 
undergone total thyroidectomies. In these patients, replacement therapy 
for calcitonin is not indicated because there is no visible evidence of 
abnormalities in skeletal metabolism or of calcium and phosphate 
1 3 
regulation. Conversely, in patients with medullary carcinoma of the 
thyroid gland, the levels of calcitonin are thousands of times greater than 
healthy adults. In these patients, no hypocalcaemia is observed. As a 
result of these findings, some researchers have characterized calcitonin 
as being a "vestigial" hormone in adult humans 123, 124. Clinically 
however, calcitonin has shown some promise. Recently, salmon 
calcitonin and synthetic human calcitonin has shown great potency in the 
treatment of Paget's disease of bone by blocking bone resorption 124. 
To further investigate the therapeutic use of calcitonin, we propose 
to construct dye-cysteine conjugates as model systems incorporating 
both Azure A and Azure B as the dye components. In these conjugates, 
Azure A and Azure B (Figures 5 and 7), will function as the 
photosensitizers and will be chemically bound via an activated linker to 
its terminal primary amine and secondary amino group, respectively. 
N~ 
H'-.. + 
N s N(C lib I 
CliJ er 
Fig. 7. 
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Since these dyes are impure and the synthesis of the activated dye linker 
molecule generates many side products, a detailed separation strategy 
will be performed to purify this molecule. After purification, the activated 
Azure B dye linker molecule will be chemically combined with bovine 
and rat calcitonin (Figure 8) respectively, to give dye peptide 
conjugates. These dye peptide conjugates will specifically bind to their 
receptor sites. 
lys-Gly-Asn-Leu-tler-Thrjysoet\1e~Leu-01 )-Tltr-T'vT 
Gl1T9Pro...Phe..J'lu-liis-Ph-.Lys..As!W.eu-A.sp.Gtn. Jhr 
ki-se~e--Oly-l/ al-<JlrAlar-Pro-l'JH2 
Fig. 8. 
Upon irradiation of this site. the energy from the light will be transferred 
either directly to the receptor via the excited photosensitizer or through 
the agency of singlet oxygen. Elements in the receptor site will be 
irreversibly disrupted or oxidized causing a lethal reaction in the 
surrounding tissue. The biological results as well as radionuclide studies 
will be reported elsewhere. 
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Statement of Purpose 
The work presented in this dissertation represents a novel attempt 
at building structural specificity on to a dye via a linker and a receptor 
specific peptide chain. In particular, we propose to construct dye 
cysteine conjugates as model systems incorporating both Azure A and 
Azure B as the dye components. In these conjugates, Azure A and Azure 
B will function as the photosensitizers and will be chemically bound via 
an activated linker.to its terminal primary amine and secondary amino 
group, respectively. After purification, the activated dye linker molecule 
will be chemically combined with bovine and rat calcitonin, respectively, 
to give dye peptide conjugates. Upon irradiation of this site, the energy 
from the light will be transferred either directly to the receptor via the 
excited photosensitizer or through the agency of singlet oxygen. 
Elements in the receptor site will be irreversibly disrupted or oxidized 
causing a lethal reaction in the surrounding tissue. This methodology, if 
successful, could lead to better understanding of the SAR profile of 
calcitonin and its use clinically in adult humans. The synthetic scheme 
for the construction of this novel dye-peptide conjugate is illustrated in 
Chapter II. The biological results will be reported elsewhere. 
CHAPTER II 
RESULTS AND DISCUSSION 
Synthesis of N-t-Butyloxycarbonyl-2-chloroethylamine ( 1) and N-
aminoethyl Azure B (2) (Schemes 1, 2) 
A. Synthesis of N-t-Butyloxycarbonyl-2-chloroethylamine ( 1) 
The synthesis of N-t-Butyloxycarbonyl-2-chloroethylamine (1) was 
attempted using a literature procedure.40 Sodium chloride and sodium 
bicarbonate were dissolved in water and set aside. DH-Butyl 
dicarbonate and 2-chloroethylamine were dissolved in anhydrous 
chloroform and the reserved salt solution was added to the chloroform 
solution. The slurry was heated to 85 oc and refluxed for 3 h. The 
reaction mixture was analyzed by tic and the reaction was found to be 
85% complete giving one product spot. The reaction mixture was cooled 
to ambient temperature and work-up was performed as detailed in 
Chapter Ill to give a yellow oily residue. The yellow oil was carefully 
distilled under vacuum to give pure N-t-Butyloxycarbonyl-2-chloroethyl-
amine in moderate yield. If the distillation apparatus is heated too quickly 
1 6 
or vacuum is applied too late in the process, the material rapidly 
decomposes to a brown tarry substance. 
+ 
0 l 
A~ /Cl 
\ ..,..0 N/ "'-v/ 
"\ 
( 1) 
Scheme 1 
B. Synthesis of N-aminoethyl Azure B (2) 
1 7 
The reaction conditions for the following transformation originated 
from an unpublished procedure that claimed to have formed N-
aminoethyl Azure B in poor yield. Azure B was dissolved in 1 O ml 
anhydrous DMSO and stirred at ambient temperature. N-t-
Butyloxycarbonyl-2-chloroethylamine (1) was dissolved in 2 ml 
anhydrous DMSO and set aside. Potassium t-butoxide was added to the 
stirring Azure B solution. The reaction mixture color changed from dark 
1 B 
blue to a brilliant purple color within 3 min. N-t-butyloxycarbonyl-2-
chloroethyl amine (1) solution was added dropwise to the purple, Azure 
B mixture and this reaction solution was heated to 100 oc for 5 h. At 5 h, 
the reaction solution returned to a dark blue color. Tic analysis was 
difficult owing to the DMSO in the reaction mixture. The smeared tic 
result showed the reaction to be 60-70% complete, resulting in at least 5 
products. The reaction mixture was cooled to room temperature. An 
aliquot of the reaction mixture was added to a separatory funnel 
containing 50 ml EtOAc and was washed 10 x with 100 ml portions of 
brine. The organic layer was slightly colored with blue compound but the 
DMSO and most of the compound partitioned into the brine layer! Since 
direct organic work-up appeared not to be an option for preliminary 
washing of the crude mixture, the DMSO solution was loaded on to a 
chromatography column using a chloroform/methanol gradient as eluent. 
The column was immediately stained a dark blue color as soon as the 
sample was allowed to flow through the column, making band tracking 
impossible. Fractions were collected and combined based on perceived 
product presence via tic. Several groups of potential product mixtures 
and co-eluted DMSO, were combined. As luck would have it, one group 
of fractions appeared to have an enriched amount of the desired material 
as determined by comparing the proton NMR's of the fractions with an 
authentic sample. The reaction clearly gave many products and 40% 
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Azure B remained unreacted in the mixture. Following reaction progress 
by tic was made unmanageable by the reaction solvent, DMSO, and the 
lack of available authentic product (2). The yield for this reaction was 
very poor and this procedure was abandoned as a preparative method 
for the synthesis of (2). 
Synthesis of Methylene Blue (7). An Eschweiler-Clarke reductive 
alkylation with formalin. (Scheme 3) 
A. Methylene Blue (7). The reaction with formalin. 
Since the basicity of the secondary amine on Azure B was 
undetermined, an alkylation of the amine group using Eschweiler-Clarke 
methodology 132 was thought to be a good model reaction to 
approximate the basic behavior of the amine group. The product of this 
reaction, Methylene Blue, is readily available from Aldrich as an 80% 
pure blue solid. Azure B and Methylene Blue are readily separable by tic 
or via reversed phase hplc. With authentic product in hand and a reliable 
monitoring system available, the reaction appeared to fairly 
straightforward. Azure B was dissolved in anhydrous methanol and 
formalin and acetic acid were added dropwise to the stirring blue 
solution. The mixture was heated in an oil bath at 80 oc. Sodium 
cyanoborohydride was added to the heated solution all at once. The 
solution became a nearly unstirrable, bubbly, dark blue slurry. The 
reaction mixture became stirrable after 1 h at 80 oc. 
ONn~ + H, ~ N S + 
CIH N(CH3)2 3 er 
Scheme 2 
0 
\_.......0AN~c1 
--\ (1) 
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The heating bath was removed and the reaction was stirred at ambient 
temperature for 18 h. Upon returning, the reaction was 85% complete, 
affording a single product that co-spotted with Methylene Blue on tic. The 
product had the exact retention time as Methylene Blue via hplc 
2 1 
(Table 1 ). The reaction showed some evidence of borohycride complex 
formation. The blue reaction mixture was diluted with methylene chloride 
and the residue was suction filtered to give a blue solid. The filtrate was 
concentrated down to a blue solid. The suction filtered solid was found to 
predominantly contain borohycride complex and salts. The solid derived 
from the filtrate was enriched with Methylene Blue. 
Cl 
Cl 
(7) 
Scheme 3 
22 
Since the procedure gave a fairly clean reaction, it was concluded that 
this approach could be extended to the preparation of N-aminoethyl 
Azure B (2) provided that the appropriate amino aldehyde be prepared. 
Synthesis of N-Carbobenzyloxyethanolamine ( 3), 
N- C arboben zyl oxyam in om ethan al ( 4), 2-( N-Carbobenzyloxyam i no)-
eth an al ( 5), N-Carbobenzyloxymethanolamine-N-2-
aminoethanoate ( 6), N-t-Butyloxycarbonyl-ethanolamine ( 8), and 
N-t-Butyloxycarbonyl-ethanolamine methanoate ( 10) 
(Schemes 4, 5, 6, 7) 
A. Synthesis of N-Carbobenzyloxy-ethanolamine (3) 
In order to form the desired aldehyde, we first needed to protect a 
building block. Ethanolamine is sold by Aldrich as a viscous liquid that is 
fairly inexpensive. As a first protecting group, I chose the Cbz group 
because of its ease of formation. NCbzNHS ( 40 g) was dissolved in 
anhydrous methylene chloride (100 ml) and stirred at room temperature. 
DMAP was added in a catalytic amount to ensure quantitative reaction. 
The reaction mixture was cooled to -10 oc and ethanolamine (9.88 ml) 
was added dropwise to the chilled solution. The slightly yellow solution 
was stirred at -10 oc for 1 h and the ice bath was removed. At 36 h, tic 
showed 93% reaction to a less polar product. The reaction was worked 
Table 1 
Hplc traces for Azure B, Methylene Blue and (7)a, b 
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acolumn used for the analysis was a YMC Basic C1 a; 4.6 x 250 mm 
at 1 ml/min monitoring via RI and UV detection at 220 nm. Solvent 
system: 35% H20; 32.5% MeOH; 32.5% CH3CN; 3.6g/L K2HP04; 
12ml/L ethylene glycol. 
bRetention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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up in the usual fashion to give a white solid. The solid was dissolved in 
the minimum amount of hot ethyl acetate and placed in a -25 oc freezer. 
White crystals were harvested from the liquor using cold ethyl acetate as 
a wash. The crystals were dried in vacuo to give 64% yield of N-
Carbobenzyloxyethanolamine (3). 
H2N~ 
OH 
CbzN\. A. 
+ NCbzNH~s---·· v "OH 
(3) 
Scheme 4 
B. Synthesis of N-Carbobenzyloxyaminomethanal (4), 
2-( N-Carbobenzyloxyamino)-ethanal ( 5), 
N-Carbobenzyloxymethanolamine-N-2-aminoethanoate (6) 
With the protected amino-alcohol in hand, all that was needed was 
to oxidize the primary hydroxyl to an aldehyde. The first oxidation 
attempts included the use of the Swem oxidation, Corey-Kim oxidation 
and Mn02 conditions78_ All of the experiments resulted in recovery of 
starting material after work-up. The next series of experiments used 
pyridinium chlorochromate (PCC) as the oxidizing agent. Using a 
procedure described by Piancatelli and co-workers, 79, 93 
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N-Carbobenzyloxy-ethanolamine (3) was dissolved in methylene 
chloride (100 mg/ml) and PCC (1.3 eq.) was gadually added to the 
solution. The solution turned from yellow to a dark amber color. After 
stirring this solution at RT for 2 h, the reaction was found to be 90% 
complete giving at least 3 products. The reaction mixture was quenched 
by adding ether to the solution and removing the brown precipitous 
residue with suction filtration. The filtrate was concentrated down to a 
yellow-brown oil and the residue was purified via column 
chromatography to give three products and a small amount of unreacted 
starting material. The three products were identified as the following 
compounds using Nmr, Ms, and Ir; N-Carbobenzyloxyaminomethanal 
(4), the least polar product, 2-(N-Carbobenzyloxyamino)-ethanal (5), N-
Carbobenzyloxy-methanolamine-N-2-aminoethanoate (6) in a ratio of 
about 2:0. 5:3. The desired compound, 2-(N-Carbobenzyloxyamino)-
ethanal (5), nearly co-spotted with starting material and was formed in 
only a trace amount. In order to optimise the amount of desired 
compound at the expense of side product formation, sodium acetate (1.0 
eq) was added to the reaction mixture and the reaction was also diluted 
to 6.5 mg/ml. The reaction rate was slowed but the same product 
mixture resulted. Finally another method was tried using PCC (4.1 eq), 
CaC03 ( 5 eq) and crushed 4 11. molecular sieves. This resulted in an 
even slower reaction rate as compared with the previous experiment. 
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I then decided to try the Boe protected ethanolamine to see if the results 
would be any better. 
(4) 
CbzN~ 
OH 
(3) 
1. PCC (2.08 eq) 
NaOAc (3.0 eq) 
2. PCC (2.08 eq) 
1 :2 :2 40% yield chrom 3 :2 60% yield chrom 
CbzN\A 
+ ~ 
0 
(5) (6) 
Scheme 5 
C. Synthesis of N-t-Butyloxycarbonylethanolamine ( 8) 
N-t-Butyloxycarbonylethanolamine (8) is availaible from Sigma 
Chemical company as a 95% pure oil. Because of its expense, it was 
desirable to see whether or not this compound could be made efficiently. 
A small amount of the Sigma product was retained as a reference 
sample. t-Butyl-succinimide carbonate (21 g) was dissolved in 
27 
anhydrous methylene chloride (50 ml) and stirred at room temperature. 
DMAP was added in a catalytic amount to ensure complete reaction to 
product. The reaction mixture was cooled to -1 O oc and ethanolamine 
(4.88 ml) was added dropwise to the chilled solution. The slightly yellow 
solution was stirred at -1 O oc for 1 h and the ice bath was removed. At 
18 h, tic (ninhydrin) showed 50% reaction to a less polar product that co-
spotted with authentic N-t-Butyloxycarbonylethanolamine (8). The 
reaction was worked up in the usual fashion to give a white solid. The 
solid was dissolved in the minimum amount of methylene chloride and 
the solution was loaded on to a silica gel column eluting with 
hexane/ethyl acetate and methylene chloride. The resulting fraction 
were combined to give a 50% yield of N-t-Butyloxycarbonylethanolamine 
(8) as a colorless oil. The yield might have been improved by the 
addition of more DMAP and perhaps changing the solvent to a higher 
boiling solvent such as acetonitrile. Heating this mixture may have 
resulted in a better product yield. With this pure product in hand, 
oxidation experiments were performed to obtain the t-Boc protected 
analog of ethanolamine. N-t-Butyloxycarbonylcarbonylethanolamine (8) 
was dissolved in methylene chloride (100 mg/ml) and PCC (1.3 eq.) was 
gradually added to the solution. The solution turned from yellow to a 
dark amber color. After stirring this solution at RT for 1 h, the reaction 
was found to be 100% complete giving baseline material. The reaction 
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mixture was quenched by adding ether to the solution and removing the 
brown residue with suction filtration. The filtrate was concentrated down 
to a yellow-brown oil and the residue was purified via column 
chromatography to give a ninhydrin positive, non-desired product. As 
with derivative (3), another method was tried using PCC (4.1 eq), CaC03 
(5 eq) and crushed 4 l molecular sieves. This resulted in a more 
complex mixture and 50% unreacted starting material. I decided then to 
try a preparation using N-t-Butyloxycarbonylethanolamine methanoate 
(10) as the starting material. 
(8) 
Scheme 6 
D. The attemped synthesis of 2-(N-t-Butyloxycarbonyl)-
ethanal ( 1 Oa) 
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Since little success was realized by the use of the oxidation 
methods attempted so far, additional approaches were sought in order to 
prepare the desired amino-aldehyde. Another approach to the formation 
of the desired amino-aldehydes was found in the literature. Rich and co-
workers used protected esters of branched amino acids to form amino-
aldehydes 80,81. The method they used consisted of making or buying 
the protected amino acid, making the methyl ester of this amino acid 
83,85,96 and treating the ester with DIBAL-H to give the protected amino-
aldehyde of choice. This reductive approach seemed like it would be 
mild enough that dimerization and oxidative cleavage side reactions 
were unlikely to occur. N-t-Butyloxycarbonyl-glycine was purchased from 
Sigma and used without further purification. N-t-Butyloxycarbonyl-
glycine was dissolved in anhydrous DMF and sodium bicarbonate was 
added to the solution to make a white slurry. Methyl iodide was added 
dropwise to the slurry and the reaction mixture was stirred at ambient 
temperature for 18 h. After 18 h, the solution had turned yellow and tic 
showed 50% reaction to a less polar, ninhydrin ( +), product. At 36 h, the 
reaction was shown by tic to be 65% complete. The reaction was 
quenched using ethyl acetate and 5% sodium bicarbonate and the 
organic layer was pumped on under high vacuum leaving a yellow solid. 
The residue was purified via column chromatography to give pure N-t-
Butyloxycarbonylethanolamine methanoate (10) in 35% yield. The 
DIBAL-H reduction of N-t-butyloxycarbonylethanolamine methanoate 
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(1 O) was carried out using freshly distilled toluene. The reaction mixture 
was cooled to -78 oc via a dry ice/ acetone bath. DIBAL-H (1 M, 2.5 eq; 
hexane) was added dropwise to the stirring, chilled solution. After 10 
min, the solution had turned from slightly colored to colorless. In the Rich 
paper, the reaction example was converted to product within 10 min. The 
reaction was then sampled and the tic showed 100% conversion to a 
more polar product. The reaction mixture was quenched with a 10% 
solution of Rochelles salt, warmed to room temperature, and partitioned 
with ethyl ether. The organic phase was dried over anhydrous sodium 
sulfate, filtered and concentrated down to an oil. The oil was purified via 
column chromatography to give 50% yield of a white solid that was 
unidentified, but it was probably not the desired (1 0) but rather an 
aluminum salt complex. In my experience, the work-up procedure for 
DIBAL-H reactions seems to be key in the isolation of product. Many 
times if the work-up procedure has the wrong combination of water or 
solvent, the product would become trapped as an aluminum salt in the 
resulting emulsion. In this case, the literature work-up procedure was 
inadequate in dealing with the emulsion problems I experienced during 
the work-up of this reaction. The starting material I used in this reaction 
was derived from an unbranched amino acid. Curiously, Rich only used 
3 1 
branched amino acids in his publications. The structural differences in 
starting materials may have played a role in the reaction results as well 
as affecting the work-up of the experiment. 
C Jitl ~ . 1 eq)-----i•-
( 1 0) 
Scheme 7 
Synthesis of 2-(N-t-Butyloxycarbonylamino)-ethyl-2-methane 
sulfon ate ( 9), 2-( N-C arbobenzyl oxya min o )-eth yl-2-methan e 
sulfonate (11) (Schemes 8, 9) 
Athough I had observed precedent for the successful extension of 
Eschweiler-Clarke methodology to the Azure B system, I could not 
prepare 2-N-Carbobenzyloxyamino-ethanal (5) in reasonable yields. 
This then led me back to the "nucleophilic" approach for the preparation 
of N-aminoethyl Azure B (2). It was observed that an aniline amide could 
be deprotonated by treatment of the substrate with 3-4 eq of NaH in DMF 
at ambient temperature 131. This observation made me hopeful that 
extension of this methodology to Azure B, coupled with the appropriate 
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activated electrophile, would lead to the desired N-aminoethyl Azure B 
(2). To this end, I decided to prepare the mesylate of 
N-t-Butyloxycarbonylethanolamine ( 8) and N-Carbobenzyloxy-
ethanolamine (3). As luck would have it, during the course of preparing 
the intermediates for this "nucleophilic" approach, I discovered yet 
another literature reference for the preparation of amino-aldehydes of 
amino acids. This literature method by Luly 97 and co-workers 
demonstrated that the preparation of unbranched amino-aldehydes is not 
trivial. 
A. 2-( N-t-Butyloxycarbonylamino)-ethyl-2-methane sulfonate 
(9) 
N-t-Butyloxycarbonyl-ethanolamine (8) (95% solution Sigma) was 
dissolved in freshly distilled, anhydrous pyridine and stirred at ambient 
temperature under N2. Experience has shown that freshly distilled 
pyridine will lead to a purer product with higher yields. Methanesulfonyl 
chloride (1.5 eq) was added dropwise to the stirring clear solution. The 
reaction was stirred at room temperature for 18 h. Tic showed 75% 
reaction to one slightly less polar product and another highly non-polar 
product. The stain used to monitor the reaction was ninhydrin. The 
reaction was quenched in the usual way using saturated copper sulfate 
solution and methylene chloride. The brown solid was chromatographed 
on a silica gel column to give 2-( N-t-Butyloxycarbonylamino)-ethyl-2-
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methane sulfonate (9) as an off-white oil that solidified upon standing in 
45% yield. After 30 days at ambient temperature in a high vacuum oven 
under P205, N-t-Butyloxycarbonyl-N-ethyl-2-methane sulfonic ester (9) 
decomposes to liberate N-t-butyloxycarbonyl-ethanolamine (8). 2-(N-t-
Butyloxycarbonylamino)-ethyl-2-methane sulfonate (9) is stable if stored 
at -25 oc or used within a few days of preparation. 
Boe~ 
OH 
(8) (9) 
Scheme 8 
B. 2-( N-Carbobenzyloxyamino)-ethyl-2-methane sulfonate 
( 11 ) 
N-Carbobenzyloxy-ethanolamine (3) was dissolved in freshly 
distilled, anhydrous pyridine and stirred at ambient temperature under 
N2. Experience has shown that freshly distilled pyridine will lead to a 
purer product at higher yields. Methanesulfonyl chloride (1.5 eq.) was 
added dropwise to the stirring clear solution. The reaction was stirred at 
room temperature for 18 h. Tic showed 95% reaction to a slightly less 
polar product. The reaction was quenched in the usual way using 
saturated copper sulfate solution and methylene chloride. The brown 
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solid was chromatographed on a silica gel column to give 2-(N-
Carbobenzyloxyamino)-ethyl-2-methane sulfonate (11) as a white solid 
in 52% yield. 2-( N-Carbobenzyloxyamino)-ethyl-2-methane sulfonate 
(11) can be stored as pure solid at ambient temperature in a high 
vacuum oven under P205 for several months without observing any 
decomposition. A better synthetic procedure for the preparation of N-
Carbobenzyloxy-ethanolamine (3) used methanesulfonyl chloride ( 1. 5 
eq) with methylene chloride as the solvent, and DMAP (1.2 eq) as a 
catalyst. The reaction is complete within 18 h, and workup procedures 
involve the use of 10% HCI followed by 5% NaHC03 followed by a final 
brine wash. After column chromatography, the yield improves to 84%. 
CbzN~ 
OH 
(3) ( 11 ) 
Scheme 9 
Synthesis of N-ammonium ethyl Azure B (2a), N-
Carbobenzyloxy-amino-ethyl Azure B (2b), N-aminoethyl-2-
chloroethanamide-Azure B ( 1 2), N-aminoethyl-2-
iodoethanamide-Azure B (13) (Schemes 10, 11, 12, 13, 14) 
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A. N-ammonium ethyl Azure B (2a) 
The unprecedented coupling of 2-(N-Carbobenzyloxyamino)-
ethyl-2-methane sulfonate ( 11) to Azure B proved to be quite a challenge 
not only from a synthetic standpoint, but from a purification standpoint as 
well. To this end, hplc has been a great deal of help in discriminating 
one blue fraction from another. However, since the detection system only 
monitors the UV of the sample, an apparently pure sample by UV 
frequently contains many UV transparent impurities. Analysis of the 
reaction using tic has been unreliable. 2-(N-Carbobenzyloxyamino)-
ethyl-2-methane sulfonate (11) was dissolved in anhydrous DMF at 
ambient temperature under N2 and set aside. Azure B (Aldrich) (1g; 1 
eq; 3. 7 mmol) was dissolved in anhydrous DMF at ambient temperature 
under N2. Sodium hydride (80% dispersion in mineral oil, Aldrich) (1.13 
g; 4 eq) was added portionwise to the stirring blue solution. Upon 
addition of the base, the reaction foamed and turned from blue to a 
reddish-purple color. This anion solution was stirred at ambient 
temperature for 10-15 min. The mesylate solution was added ctopwise 
to the anion solution and the reaction was stirred at ambient temp for 30 
min. Hplc analysis of the reaction showed nearly 85% complete reaction 
(Table 2). The reaction was quenched by the addition of 1-2 ml 10% 
HCI solution and then was subsequently frozen to a near solid using a 
dry ice/ acetone bath and lyophilized for 18 h. Preparative hplc of the 
crude mixture gave a small amount (1 O mg from 200 mg) of desired 
product from the solid residue. Preparative tic gave unreliable 
separation of components in the crude reaction mixture. However, 
conventional chromatog-aphy (CH2Cl2:MeOH (10: 1.5); 70-230 Mesh 
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gel; Merck) gave a small amount of mixed product while the remaining 
loaded compound was not eluted. The purification problem was 
resolved by pre-treating the silica gel with EtOH: Ammonium Hydroxide 
(3:1) and filtering the slurry through a micropore filtration apparatus prior 
to suspending in solvent system. From 1 g of crude product, I was able to 
get 300-400 mg 85%+ pure product. Since removal of DMF was a 
problem, especially at a scale larger than 1 g starting material, 
acetonitrile and THF were tried as other solvent candidates. After two 
days, the reaction using acetonitrile was 10% complete. Alternatively, 
after two days, the reaction using THF was about 60-70% complete. THF 
(anhydrous) then became the solvent of choice. There were several 
differences in the rate of reaction using THF and DMF. By the use of THF 
as the solvent, the preactivation of the Azure B substrate using NaH had 
to be lengthened to 1 h. Additionally, using THF as the solvent slowed 
the reaction. This result could be explained because Azure B is 
sparingly soluble in THF but is completely soluble in DMF. However, the 
reaction in THF quenches nicely with acid and can be concentrated to a 
solid under reduced pressure. The residue can then be purified using 
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the improved chromatogaphy approach to give 300 mg N-ammmonium 
ethyl Azure B (2a) from 1 g Azure B. The other major problem 
encountered when working with this compound was the acquisition of 
resolved 1 H and 13c Nmr spectra using the familiar two solvent 
(CDCl3:CD30D; 3:1) methods. For whatever reason, the Nmr 
technology at Loyola will not permit a lock on my samples dissolved in 
this solvent mixture. I then had to use C030D as the Nmr solvent. My 
compound dissolves in CD30D but the resolution of the Nmr spectra is 
not superior to the two solvent (COCl3:CD30D; 3:1) method. 
CbzN' A 
V "oMs 
( 11 ) 
+ er 
H3N~N 
I 
CH3 
Cl 
(2a) er 
Scheme 10 
Azure B 
Table two 
Hplc traces for Azure B and (2a)a,b 
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acolumn used for the analysis was a YMC ODS-AQ C1 a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 73% 
H20; 27% CH3CN; 0.1% TFA. 
bRetention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
39 
The Nmr analysis of both the proton of carbon spectra of the 
parent, Azure B (2) and product (2a), proved to be very difficult. The 
carbon spectra of Azure B not only shows that the compound available 
from Aldrich contains impurities, but that there are equilibrating forms of 
Azure B. This is evident in the carbon spectra by many broadened 
peaks. Attempts to purify Azure B using preparative tic, extraction, and 
column chromatography resulted in slightly purer material at great effort. 
The carbon spectra of (2a) likewise shows peak. broadening but to a 
lesser extent. To help us further assign peaks, carbon spectra were 
derived for most of my compounds using the ACD/CNMR computer 
program sold by Advanced Chemistry Development, Inc., Toronto, 
Canada. The carbon spectra for most of the significant compounds in the 
dissertation were predicted using this program. The carbon spectra were 
reasonably predicted for most of the less complex compounds in this 
dissertation and in most cases, were identical to the actual carbon 
spectra for the compounds. Since the ACD program was found useful for 
the less complex compounds covered in this dissertation, we were 
reasonably confident that the program would reliably predict the carbon 
spectra for the more complex compounds in this dissertation. In nearly 
all of the cases, the actual carbon spectra fell within the limits predicted 
for the theoretical carbon spectra derived from the ACD program. 
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B. N-Carbobenzyloxyl-amino-ethyl Azure B (2b) 
The synthesis of N-Carbobenzyloxy-N-ethyl Azure B ( 2b) was 
initiated in order to trap the terminal primary amine of (2a) and hopefully 
give us Nmr spectra that are more straightforward to interpret. N-
ammonium ethyl Azure B (2a) (0.040 g; 0.13 mmol) was dissolved in a 
mixture of 1 ml methylene chloride and 1 ml MeOH. This was stirred at 
ambient temperature under nitrogen. D MAP ( 0. 015 g; 1 eq) was added 
to the mixture followed by NCbzNHS (0.048 g; 1.5 eq). The resulting 
mixture was stirred at room temperature under nitrogen for 24 h. At 24 h, 
tic showed 85% complete reaction to a less polar product. The dark 
purple reaction mixture was quenched by evaporating the solvent and 
the resulting solid was diluted with the minimum amount methylene 
chloride/MeOH and loaded on to a preparative tic plate. The resulting 
purified product was analyzed via Nmr, hplc and Ir. The Nmr resuts were 
not as clear as we had hoped. In particular, the aromatic region shows 
evidence of pi stacking due to the complexity of the signal splitting. 
However, this region integ-ates nicely to approximately the required 11-
12 protons needed to prove the structure. The hplc results are shown in 
Table 3. 
4 1 
+ er 
H3N~N + 
I s N(CH 3) 2 
CH3 (2a) Cl-
Qo NCbzNHS DMAP 
o-f 
N N ~ 
< 
~ 
+ 
N s N(CH3)2 I 
CH3 (2b) Cl 
Scheme 11 
C. N-aminoethyl-2-chloroethanamide-Azure B ( 12) 
The synthesis of N-aminoethyl-2-chloroethanamide-Azure B ( 12) 
was initiated using a previous student's conditions. These conditions 
included the use of greater than 400 fold excess of chloroacetyl chloride 
to substrate. In my hands, this method led to many reaction products and 
results that varied from experiment to experiment. 
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Table 3 
Hplc traces for (2a) and (2b)a,b 
(2b) 
acolumn used for the analysis was a YMC ODS-AQ C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 77% 
H20; 23% CH3CN; 0.1% TFA. 
bRetention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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A search was then conducted to see if more reliable conditions could be 
worked out to give controlled, reproducible formation of N-aminoethyl-2-
chloroethanamide-Azure B (12). Schotten-Bauman conditions 
85, 103, 104, 106 have been used for decades as a method of acylation of 
amines to form amides. I first chose a modification of this method that 
used an activated pyridinium-acetyl chloromethyl complex which would 
then rapidly react with the free amine in N-aminoethyl Azure B (2). 
Additionally, the system would have an acid scavenger in s!lu for the 
neutralization of generated HCI. The reaction was performed in 
anhydrous acetonitrile. The substrate, N-aminoethyl Azure B (2), was 
only sparingly soluble in this solvent, so care was taken to make sure the 
compound was scraped off the side of the flask and exposed to reaction 
conditions. Both pyridine and chloroacetyl chloride must be freshly 
distilled in order to decrease side product formation. N-aminoethyl Azure 
B (2) (0. 5 g; 1 eq; 1.6 mmol) was slurried in 5 ml of acetonitrile at 
ambient temperature under N2 and set aside. Acetonitrile (2.5 ml) was 
added to a round bottom flask at ambient temperature under N2 and 
pyridine (0.5 ml; 4 eq) was added to the acetonitrile. The solution was 
colorless at this point. Chloroacetyl chloride ( 0. 5 ml; 4 eq) was rapidly 
added to the pyridine solution and the resulting bright orange solution 
was added to the substrate solution. The reaction was stirred for 18-36 h 
while monitoring the reaction via hplc. The deep blue-green reaction 
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mixture was usually quenched at 36 h by pouring into a separatory 
funnel containing chloroform and water. The organic phase and 
aqueous phase were analyzed via hplc for product partitioning. Only a 
small amount of product has been detected to partition into the aqueous 
layer. The resulting organic phase was washed with brine and 
anhydrous sodium sulfate, filtered and concentrated down to a deep 
blue-green semisolid. The resulting product was purified via column 
chromatography (CH2Cl2:MeOH (10: 1.5)) to give 100 mg of 65% N-
aminoethyl-2-chloroethanamide-Azure B (12). For some reason, no 
matter how careful the chromatography, the most polar product (brownish 
material) elutes with the desired product giving impure product sample 
as well as imparting a more yellow color to product giving the product a 
definite blue-green color. Nmr analysis of (12) showed a great deal of 
coupling and unanticipated chemical shifts. The Nmr spectra of ( 1 2) 
were compared with 2-chloroacetamide (Aldrich). ACD generated 
theoretical spectra were derived in order to better understand the actual 
Nmr spectra of (12) by comparison. The large amount of side-product 
generated in this reaction prompted me to search for a more controlled 
synthetic approach to the target (Table 4). An alternative approach to the 
desired N-aminoethyl-2-chloroethanamide-Azure B ( 1 2) was attempted 
using a coupling method found in amino acid chemistry· 
DCC (Dicyclohexylcarbodiimide) has been widely used as a 
coupling agent in peptide chemistry 100_ According to theory. a 
preactivated complex of DCC and chloroacetic acid should lead to the 
+ er 
H3N~N 
I 
eH3 (2a) 
Scheme 12 
er 
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desired product, (12), when combined with the free amine, N-aminoethyl 
Azure B (2). DCC (1.5 eq; distilled under vacuum) was dissolved in 
freshly distilled THF. Chloroacetic acid (1 eq; recrystallized from 
chloroform) was added to the DCC. The resulting slurry was stirred for 
0.5 h. N-ammonium ethyl Azure B (2a) (1eq) was dissolved in THF and 
(2a) 
Table 4 
Hplc traces for (2a) and (12)a,b 
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acolumn used for the analysis was a YMC ODS-AO C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 77% 
H20; 23% CH3CN; 0.1% TFA. 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
47 
set aside. Hunig's base (1 eq) was added to (2a) just prior to the addition 
of the substrate solution to the DCC slurry. The free amine, (2), was 
added dropwise to the DCC slurry. The resulting blue slurry was stirred 
at RT for 36 h. The reaction was quenched by diluting with MeOH and 
filtering off the DCU (dicyclohexylurea) via suction filtration. The filtrate 
was concentrated down to a deep blue-green semisolid. The crude 
sample was analyzed via hplc and found to be enriched with (12). The 
product derived from this method also had the same retention time as the 
product from the Schotten-Bauman procedure. The crude product was 
purified via column chromatography (CH2Cl2:MeOH (10: 1.5)). A 
previous student reported that addition of crude chloroacetamide, ( 12), to 
an -SH terminus of a peptide, resulted in selective displacement of the 
chloride by the sulfur. As a test example, I attempted to react N-
aminoethyl-2-chloroethanamide-Azure B (12) with L-Cysteine. 
According to convention, the desired pH for the reaction was found to be 
8. 5-9.0 30,95,96, 107, 109. This was achieved by the use of boric acid 
buffer or Tris buffer. The procedure used was exactly the same as cited 
in Part 7 for the preparation of ( 1 5 ). The reaction resulted in the recovery 
of starting material as a blue solid. After column chromatography, the first 
fractions isolated contained blue colored Cysteine. This first result 
demonstrates that blue color in fractions does not necessarily mean the 
fractions contain desired product. The later fractions eluted contained 
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only N-aminoethyl-2-chloroethanamide-Azure B (12). Consistent with 
conventional wisdom and literature 30, 107, 109, 110, 111 precedent, this 
experiment demonstrates that chloroacetamide displacement is unlikely 
with either -SH or -NH termini. 
D. N-aminoethyl-2-iodoethanamide-Azure B ( 13) 
lodoacetamides have been widely used as reactive intermediates 
in the displacement/coupling reaction between thiols, especially when 
free amino groups are present in the same molecule as the thiol group 
(L-Cysteine as a reactive terminus for example) 30, 107, 109, 110, 111. In 
peptide chemistry, radiolabeled iodoacetamides (1251) have been used 
to investigate the number of -SH linkages or disulfide bridges contained 
within a novel protein or peptide 99, 107, 110, 111. Because of the 
overwhelming amount of literature precedent in this area, I felt confident 
that coupling a thiol to a species containing an iodide would be 
reasonably successful. N-aminoethyl-2-chloroethanamide-Azure B ( 1 2) 
was then converted to N-aminoethyl-2-iodoethanamide-Azure B (13) 
using Finklestein methodology. Both acetone and THF must be freshly 
distilled otherwise the reaction will proceed only to 50%. Additionally, 
iodoacetamides are very sensitive to light so the reaction vessel needs to 
covered with foil and room lighting needs to be dim in the vicinity of the 
reaction. All sample transfers likewise need to be shielded from light and 
(12) 
Table 5 
Hplc traces for (12) and (13)a,b 
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acolumn used for the analysis was a YMC ODS-AO C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 73% 
H20; 27% CH3CN; 0.1% TFA. 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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the manipulations need to be carried out rapidly. N-aminoethyl-2-
chloroethanamide-Azure B (12) (0.01 g; 1 eq; 0.025 mmol) was 
dissolved in 0.5 ml of THF and 0.5 ml acetone at ambient temperature 
under N2. Sodium Iodide (0.0082 g; 2.2 eq.) was added rapidly to the 
stirring substrate solution. The reaction was monitored via hplc. At 18 h, 
the reaction was complete (Table 5). The resulting blue-green reaction 
mixture was concentrated down ii? vacuo while covered to give a deep 
blue-green solid. Another literature method for the formation of the 
iodoacetamide involves the direct alkylation of the amine with N-
hydroxysuccinimide-iodoacetic acid 30. (Scheme 14). This alkylation 
has several advantages over the previous pathway. It allows for the 
direct use of the free amine (2) in a mild reaction with the activated 
alkylating agent, N-hydroxysuccinimide-iodoacetic acid. There are 
several advantages to this approach. First, since iodide displacement by 
-SH groups has been shown to be selective, there is no need to protect -
NH groups or to prove if -NH or -SH displaced the iodine. The resulting 
compound already contains the iodo terminus thereby avoiding the 
synthesis of N-aminoethyl-2-chlororethanamide-Azure B ( 1 2). The 
major crawback to this method is the cost of the reactant, N-hydroxy 
succinimide iodoacetic acid. N-Hydroxy succinimide iodoacetic acid is 
sold by Sigma for roughly $83.00/100 mg. After devising a synthetic 
scheme for preparation of this reagent, I found that the cost of the 
5 1 
intermediates exceeded the cost of buying the reagent from Sigma. (2a) 
(0.028 g; 0.086 mmol), was added to a foil covered flask containing 0.5 
ml of anhydrous chloroform and 0. 5 ml anhydrous MeOH. 
H 
I 
Cl~N~7 + s N(CH3)2 
-
0 CH3 Cl 
( 12) 
l 
N ~ H ~ 
I 
1/[(~7 + s N(CH3)2 
0 CH3 
( 13) 
Scheme 13 
This mixture was stirred under nitrogen at ambient temperature. Hunig's 
base (0.022 ml; 1.5 eq) was added to the dye and the mixture was 
stirred for 5 min. NHSIAA (0.027 mg; 1 eq) was added to the mixture and 
the reaction was stirred at ambient temperature for 18 h. The reaction 
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mixture was quenched by evaporating to dryness. During this process 
no heat was employed to facilitate the evaporating process and the flask 
remained shielded from light by a foil covering. Hplc analysis of the 
crude showed a single product peak at around 15 min (77% H20; 23% 
CH3CN; 0.1 % TFA). Additionally, the resulting product, N-aminoethyl-2-
iodoethanamide-Azure B (13), can be purified via flash column 
chromatography without decomposition. provided the purification is 
performed in dim light. Preparative hplc results in decomposition of the 
iodoacetamide. An experimental proof of this can be found in Part 7 B. 
This experiment demonstrated that free iodine was present in a 
preparative hplc sample of iodoacetamide suggesting decomposition of 
the iodoacetamide on the column. In order to ensure stability of the 
iodoacetamide, the purified solid must be kept covered and refrigerated 
at around 20 oc or colder and used immediately if possible. 
(Table 6). Nmr analysis of the purified iodoaceamide (13) was done in 
CD30D as the solvent. The spectra show evidence of peak broadening 
and decomposition. 
Since both the Finklestein and the NHSIAA approaches to the 
formation of (13) were shown to be reasonably successful, the search 
was made for a synthetic method that would maximize the formation of 
(13) but minimize the cost to achieve this. While conducting a literature 
search, an interesting article was found in a recent issue of 
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J. Med C/Jem .. in which the investigators claimed to prepare 
iodoacetamides from relatively inexpensive starting materials.136 In this 
paper, Plummer and colleagues used iodoacetic acid (IAA) (98%Aldrich, 
$48.50/100 g), dicyclohexylcarbodimide (DCC) (Aldrich, $14.55/100 g), 
and 1-hyctoxybenzotriazole hydrate (HOBT) (Alcrich,$18.75125 g) as the 
reactant to form unracemized iodoacetamides. Since some of the 
reagents were on hand, I decided to try this as a method for the synthesis 
of compound (13). IAA (0.0065 g; 0.035 mmol) was dissolved in 0. 5 ml 
anhycrous DMF and was stirred at ambient temperature under nitrogen 
until the IAA dissolved. The reaction flask was covered with foil. (2a) 
(0.011 g; 0.035 mmol) was dissolved in 0.5 ml DMF and set aside. The 
amine solution was added dropwise to the IAA solution over 5 min. 
HOBT (0.0047 g; 0.035 mmol) was added to this solution followed by 
DCC (0.0073 g; 0.035 mmol) HOBT was added to the reaction even 
though the starting material contains no chiral centers.137, 138. The 
reaction was stirred at ambient temperature and monitored for 
completeness via hplc at 1 h, 3 h, 24 h, and 48 h. At 24 h, the reaction 
was found to be around 20% complete. Perhaps if base would have 
been added to facilitate free amine formation, the reaction would have 
given more product. The reaction was quenched by suction filtration of 
the reaction mixture and concentrated the filtrate under vacuum. Hplc of 
the purple residue showed that many impurities/side products had 
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formed in the reaction. About 15% of the reaction mixture was desired 
material The residue was diluted with methylene chloride and flash 
chromatographed with methylene chloride followed by a gadient using 
the minimum amount of methanol. The Nmr analysis of the purified 
material showed that the product matched the product formed from the 
other methods but was further complicated by the presence of DC U in the 
product. In comparing the three method for the synthesis of (13), the 
method giving the highest yield of (13), and fewer side products is the 
method using NHSIAA.(Table 15) 
(2) 
Scheme 14 
Cf 
11. Hunig's base 2. NHSIAA 
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Table 6 
Hplc traces for (2a) and (13)a,b 
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acolumn used for the analysis was a YMC ODS-AQ C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 77% 
H20; 23% CH3CN; 0.1% TFA. 
b Retention ti mes cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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Purification of Azure A (13a) and the 
synthesis of N-iodoformamide Azure A (13b) (Scheme 1 5) 
A. 2-iodoformamide-Azure A (13b). 
While investigating the optimization of (13), I realized that the 
anion generated from the reaction of NaH with the secondary methyl 
amine of Azure B could potentially form the imine (Figure 9). If this 
process is more rapid than the displacement of the mesylate from (11 ), 
starting material would be regenerated upon work-up of the imine. 
This would result in lower yields of desired material (2a). This question 
is further complicated by the depiction of Azure B as two different 
structures by two literature sources (Figure 10). To explore this 
question, investigate SAR (structure activity relationships) as well as test 
new iodoacetamide reaction conditions, a study was initiated with Azure 
A. Azure A (13a) (Figure 11) is available from Aldrich as a crude 
mixture of at least 4 components. A major component in this sample 
(25%), is Azure B. This is evident by examining the carbon Nmr spectra 
of the crude material. As a first method of purification, preparative tic was 
attempted using 50 mg crude Azure A. Out of the four blue bands, I was 
able to separate the two least polar components ( 30 mg) from the two 
most polar bands ( 1 O mg). 
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Base 
Fig. 9. 
,N~ 
~+ 
S N(CH3)2 
Cl-
Aldrich structure 
Merck. structure 
Fig. 10. 
Nmr analysis showed that the upper bands contained the Azure A and 
Azure B while the lower bands contained some indeterminate blue 
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material. As with the other members of the methylene blue family, peak 
broadening was observed in the carbon Nmr spectra. 
H, 
N 
I 
H 
N~ 
~+ 
S N(CH 3)2 
(13a) 
Fig. 11. 
er 
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The synthesis of the iodoformamide of Azure A using the upper 
bands was initiated using the NHSIAA reagent available from Sigma and 
Hunig's base. Azure A (upper bands) (0.028 g; 0.086 mmol), was added 
to a foil covered flask containing 0.5 ml of anhydrous chloroform and 0.5 
ml anhydrous MeOH. This mixture was stirred under nitrogen at ambient 
temperature. Hunig's base (0.022 ml; 1.5 eq) was added to the dye and 
the mixture was stirred for 5 min. NHSIAA (0.027 mg; 1 eq) was added to 
the mixture and the reaction was stirred at ambient temperature for 18 h. 
The reaction mixture was quenched by evaporating to dryness. During 
this process no heat was employed to facilitate the evaporating process 
and the flask remained shielded from light by a foil covering. Hplc 
analysis of the crude showed a single product peak at around 18 min 
(77% H20; 23% CH3CN; 0.1% TFA). Unfortunately, the remainder of the 
NHSIAA was consumed in this reaction and further studies using this 
reagent with Azure A were not possible. The residue was used 
immediately to synthesize (1 Sa). 
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Table 7 
Hplc traces for (13a) (13a upper) and (13b)a,b 
acolumn used for the analysis was a YMC OOS-AQ C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 77% 
H20; 23% CH3CN; 0.1% TFA. 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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Azure A (upper bands) were also used in a reaction with 
IAA/DCC/HOBT in an attempt to form the iodoformtamide of Azure A. IAA 
(0.0065 g; 0.035 mmol) was dissolved in 0.5 ml anhycrous DMF and 
was stirred at ambient temperature under nitrogen until the IAA 
dissolved. The reaction flask was covered with foil. Azure A (0.011 g; 
0.035 mmol) was dissolved in 0.5 ml DMF and set aside. The amine 
solution was added cropwise to the IAA solution over 5 min. HOBT 
(0.0047 g; 0.035 mmol) was added to this solution followed by DCC 
(0.0073 g; 0.035 mmol). At 24h, the reaction was found to be around 
10% complete. Perhaps if base would have been added to facilitate free 
amine formation, the reaction would have given more product. The 
reaction was quenched by suction filtration of the reaction mixture and 
concentrated the filtrate under vacuum. The residue was partially 
soluble in chloroform or methylene chloride. 10 mg of this reaction 
mixture was purified via preparative tic using methylene 
chloride/methanol (1 O; 1. 5 ml) as mobile Hplc of the three bands 
showed that many impurities/side products had formed in the reaction 
with only a small amount (5-10%) of desired material present in two of 
the bands. Even though the hplc samples were kept covered and 
refrigerated, rapid degadation of the product to starting material was 
observed within a matter of days. Likewise, Nmr samples that were 
dissolved in CD30D showed rapid decomposition to starting Azure A. 
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This result suggests that the Azure A derivatives may be photooxidized 
more rapidly than the more stable Azure B derivatives. 
H, 
N 
I 
H ( 13a) Cl 
Hunig's base j 
NHSIAA 
I. ft ~N~ ~N~sAA+ I N(CH3)2 
H r 
( 1 3b) 
Scheme 15 
The synthesis of L-Cysteine methanoate ( 14), and N-aminoethyl-N-
thioethanamide-L-Cysteine methanoate-Azure B ( 1 5), 
N-thioformamide-L-Cysteine methanoate-Azure A (15a), 
Pentapeptide conjugate ( 17) (Sch em es 1 6, 17, 18, 19) 
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A. The synthesis of L-Cysteine methanoate (14) 
There are many literature precedents for the synthesis of methyl 
esters of carboxylic acids. However, in the selection of the conditions for 
the synthesis, one must keep mindful of the fact that at basic pH. free thiol 
moieties can undergo oxidative coupling that will lead to disulfide bond 
formation. Keeping this in mind, the conditions I selected used methanol 
as the methyl source with tosic acid as the catalyst/activator. The 
reaction conditions were then acidic and the methyl source was in 
excess thereby driving the equilibrium of the reaction to reactants. L-
Cysteine (Sigma Chem Co.), (2 g; 1 eq; 16. 5 mmol) was dissolved in 100 
ml of anhydrous MeOH. Tosic acid (3.9 g; 1.5 eq) was added to the 
reaction and the solution was stirred for 14 h. Tic showed the reaction to 
be 85% complete giving a single, faintly staining (ninhydrin), less polar 
product. The reaction mixture was quenched by concentrating down ;n 
vacuo to a white solid. The residue was recrystallized using the 
minimum amount of hot isopropyl alcohol. After cooling, needle-like, 
white crystals formed in the mother liquor. The crystals were isolated via 
suction filtration. The Nmr of the crystals revealed that the compound 
(14), was isolated as the tosylate salt. 
0 
---------~ HSYOCH, 
+ NH3 OTs-
(14) 
Scheme 16 
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B. N-aminoethyl-N-thioethanamide-L-Cysteine-methanoate-
Azure B (15) 
The displacement/coupling reaction of N-aminoethyl-N-
iododethanamide Azure B (13) with L-Cysteine methanoate (14) was 
chosen as a reasonable pilot reaction for the method. The pH of the 
reaction is critical for the method to ensure the desired selectivity. 
Upon consultation with peptide chemists at Abbott as well as looking at 
the literature for precedent, the desired pH for the displacement of the 
iodide by -SH was found to be 8.5-9.0 30,95,96,107,109. The pKa of the 
side chain (-SH) in L-Cysteine is 8.3 and the basic pH should free the 
thiol to react selectively and displace the iodide. Even though basic 
conditions can lead to disulfide formation, the kinetic product of the 
reaction should be the desired adduct, N-aminoethyl-N-thioethanamide-
L-Cysteine methanoate-Azure B (15). Boric acid buffer (0.2 M) (38.1 g 
boric acid; 6. 2 g borax) or Tris buffer ( 165 m L, 50 m M stock solution of 
Tris base titrated with 12 ml, 50 mM stock solution of Tris-HCI) was 
prepared and deoxygenated to give a buffer with a pH of 8. 5-8. 9. N-
aminoethyl-2-iodoethanamide-Azure B (13) (0.002 g; 1 eq; 5.14 µ.mol) 
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was dissolved in 0.25 ml THF covered and set aside. L-Cysteine 
methanoate (14) (0.003 g; 3 eq) was dissolved in 0.25 ml boric acid 
buffer and slowly stirred in a covered flask at ambient temperature. N-
aminoethyl-2-iodoethanamide-Azure B (13) solution was added to the 
buffered solution over the course of 1 min. The reaction was stirred at 
ambient temperature for 3 h and the reaction was analyzed by hplc 
(Table 8). In 3 h, all the starting material was consumed giving a slightly 
more polar product than starting material. The reaction mixture was 
concentrated in vacuo to a blue solid. If the reaction vessel is allowed to 
be exposed to light or if the iodoacetamide was derived from preparative 
hplc, the reaction changes rapidly from a blue color to colorless with a 
white-yellow precipitate forming in the clear reaction mixture. This 
observation can be attributed to the oxidizing power of free iodine in the 
mixture. In order to ensure complete reaction, the iodoacetamide must 
be pure. 
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Cl 
(14) 
Scheme 17 
C. The synthesis of N-thioformamide-L-Cysteine methanoate-
Azure A ( 15a) 
Since it was shown that the iodoacetamide of Azure A (13a) 
rapidly decomposes, the starting material was used as soon as it was 
prepared and without further purification. N-iodoformamide-Azure B 
(13b) (0.001 g; 0.026 mmol) was dissolved in 0.5 ml DMF, covered and 
set aside. L-Cysteine methanoate (14) (0.0027 g; 0.6 eq) was dissolved 
in o. 5 ml Tris HCI buffer and slowly stirred in a covered flask at ambient 
temperature. 2-iodomethamide-Azure A (14a) solution was added to the 
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Table 8 
Hplc traces for (13) and (15)a,b 
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acolumn used for the analysis was a YMC ODS-AQ C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 77% 
H20; 23% CH3CN; 0.1% TFA. 
bRetention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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buffered solution over the course of 1 min. The reaction was stirred at 
ambient temperature for 3 h and the reaction was analyzed by hplc 
(Table 9). In 3 h, 25% of the starting material was consumed. At 24 h the 
reaction was 50% complete and at 48 h the reaction mixture was shown 
to be 90% complete to give two less polar products. The reaction mixture 
was concentrated in vacuo to a blue solid. As with the parent 
iodoformamide, N-thioformamide-L-Cysteine-methanoate-Azure A ( 1 5a) 
rapidly decomposes to Azure A upon standing in MeOH. 
( 13b) cf ( 14) 
(1 5a) 
Scheme 18 
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Table 9 
Hplc traces for (13b) and (15a)a,b 
acolumn used for the analysis was a YMC ODS-AQ C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 77% 
H20; 23% CH3CN; 0.1% TFA. 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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D. The synthesis of Pentapeptide conjugate (17) 
Since the pilot reaction using the relatively inexpensive L-Cysteine 
methanoate and iodoacetamide was found to be successful, I wanted to 
see if I could extend this method to a small peptide chain that contained 
an -SH terminus. The peptide Cys-Phe-Met-Arg-Phe-NH2 
(16) was custom synthesized by Sachem and was donated to a previous 
student as a 72% peptide content, lyophilized powder. Out of the 10 mg 
that was donated, the supply that I had to work with was around 2.8 mg of 
72% peptide. Since this peptide is expensive ($4,250/1 g), I had to 
perform this reaction knowing that repeating this synthesis would be 
impossible given the lack of money for this project. Boric acid buffer (0.2 
M) (38.1 g boric acid; 6.2 g borax) or Tris buffer (165 ml, 50 mM stock 
solution of Tris base titrated with 12 ml, 50 mM stock solution of Tris-HCI) 
was prepared and deoxygenated to give a buffer with a pH of 8. 5-8. 9. N-
aminoethyl-2-iodoethanamide-Azure B (13) (0.00125 g; 1 eq; 0.241 
µ.mol) was dissolved in 0.1 ml DMF covered and set aside. 
Pentapeptide (16) (0.0028 g; 1.65 eq.) was dissolved in 0.2 ml boric 
acid buffer or Tris buffer and slowly stirred in a covered, nitrogen flushed, 
flask at ambient temperature. N-aminoethyl-2-iododethanamide Azure B 
(13) solution was slowly added to the buffered solution over the course 
of 1 min. The reaction was stirred at ambient temperature for 3 h and the 
reaction was analyzed by hplc. In 3 h, only 10% starting material was 
7 1 
consumed. The reaction was stirred at RT for 18 h (Table 10). The 
reaction mixture was concentrated in vacuo to a blue solid. The residue 
was purified on a 1 x20 cm column using Biogel-P (fine) (Bio-Rad) and 
0.1 M acetic acid as eluent. The Biogel-P was prepared according to 
Bio-Rad instructions. The buffer chosen for the elution was 0.1 M acetic 
acid. This buffer was chosen because of its use in a paper dealing with 
the purification of porcine thyrocalcitonin 11 o. The buffer was prepared 
according to a literature procedure 127. The fractions were eluted at a 
rate of around 5 mU15 min. The first blue band was eluted at fraction 10-
15, combined, and lyophilized to give less than 0.2 mg product. The 
second blue band eluted was assumed to contain unreacted 
iodoacetamide. The Nmr of the first band showed some encouraging 
results although solvent suppression techniques will have to be used to 
obtain a reasonable 1 H and 13c Nmr spectra 125.126.128-130. Hplc 
(UV detection at 254 nm) of the reaction showed two broad peaks that 
were different from starting iodoacetamide. The pentapeptide does not 
absorb well in the UV at 254 nm so analysis of hplc results based upon 
the disappearance of pentapeptide is not useful. A summary of useful 
hplc retention times can be found in Table 11. 
Phe Met /ys 
/ ............ / ' 
NH2 Arg Phe 
( 1 6) 
+ 
( 1 3) 
Scheme 19 
Synthesis of L-Cysteine ( 1 8) from Cystine, the synthesis 
of Bovine thyrocalcitonin conjugate (20) and Rat 
thyrocalcitonin conjugate (22) (Schemes 20, 21, 22) 
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A. The synthesis of L-Cysteine ( 18) 
Part of the objective of this project is to synthesize the 
thyrocalcitonin conjugate of Azure B. In order to do this, the terminal 
disulfide bridge must be broken to liberate the -SH group. Since 
thyrocalcitonin is expensive, it is desirable to try the disulfide reduction 
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on a model system. In order to explore this reaction, I chose to reduce 
the disulfide bridge in Cystine using a literature procedure 105, 108. 
Cystine (0.1 g; 0.3 mmol; 1 eq) was dissolved in 5 ml. pH 8.5, Tris buffer 
and the slurry was stirred at RT under nitrogen. Oithiothreitol (OTT) (0. 25 
g; 5 eq) was dissolved in 5 ml Tris buffer and this solution was added 
dropwise to the cystine slurry. After 2.5 h, the reaction had turned clear 
and the reaction was quenched with 10% HCI until the pH of the reaction 
was 2-3. The reaction was extracted with EtOAc to remove any 
unreacted OTT. The aqueous layer was concentrated1/7 vacuo to a white 
solid. After analysis of the residue via Nmr and comparison with an 
authentic sample of Cysteine, the reaction was shown to be successful. 
However the product was contaminated with Tris-HCI. 
0 0 HO~s-sYoH 
NH2 NH2 
1 0 
2 HsYoH 
+NH3 
c1-
(t&) 
Scheme 20 
B. The synthesis of Bovine thyrocalcitonin conjugate (20) 
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With three successful model reactions in hand (Schemes 1 7, 
18, 19), I felt confident enough to try a pilot reaction using relatively 
inexpensive bovine thyrocalcitonin. Bovine thyrocalcitonin differs from 
Human thyrocalcitonin by 18 amino acid residues. This particular lot 
(TCA powder, Sigma) of thyrocalcitonin was chosen because it was 
relatively inexpensive ($53/10 mg formulation). In comparison, a purified 
sample of Human thyrocalcitonin is sold for $200/1 mg and Chicken 
thyrocalcitonin is sold for $277/1 mg. The preparation of Bovine 
thyrocalcitonin conjugate (20) was initiated according to a literature 
procedure 111 
Table 10 
Hplc traces for (13) and (17)a.b 
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acolumn used for the analysis was a YMC ODS-AQ C1a; 4.6 x 250 mm 
at 1 ml/min monitoring via UV detection at 254 nm. Solvent system: 80% 
H20; 20% CH3CN; 0.1% TFA. 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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According to this procedure, 8 M urea was used as a denaturant. Bovine 
thyrocalcitonin (19) (0.0017 g; 0.47 µ,mol; 1 eq) was dissolved in 0.3 ml 
boric acid buffer or Tris buffer and slowly stirred in a covered, nitrogen 
flushed, flask at ambient temperature. Urea (0.4 ml; 8 M) was added to 
this solution. The mixture took about 10 min to dissolve and had a soapy 
appearance. Dithiothreitol (DTI) (0.0013 g; 1 O eq) was dissolved in 0.3 
ml Tris buffer and this solution was added dropwise to the 
thyrocalcitonin slurry. After 2.5 h, the reaction had turned clear. 
N-aminoethyl-2-iodoethanamide Azure B (13) (0.003 g; 12 eq) was 
dissolved in 0.1 ml Tris buffer at pH 8. 5 and this solution was slowly 
added to the thyrocalcitonin solution over the course of 1 min. The 
reaction was stirred at RT under nitrogen for 18 h. The reaction was 
quenched with 10% HCI until the pH of the reaction was 2-3. The 
reaction was extracted with EtOAc to remove any unreacted OTT. The 
reaction mixture was lyophilized to a blue solid. The residue was purified 
on a 1 x20 cm column using Biogel-P (fine) (Bio-Rad) and 0.1 M acetic 
acid as eluent. The Biogel-P was prepared according to Bio-Rad 
instructions. The buffer chosen for the elution was 0.1 M acetic acid. 
This buffer was chosen because of its use in a paper dealing with the 
purification of porcine thyrocalcitonin 110. The buffer was prepared 
according to a literature procedure 127. 
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Table 11 
Hplc retention times for significant compounds 
compound hplc solvent systema ret. timeb 
Azure ac see below 14 min 
(7)C see below 12 min 
Azure B 73% H20; 27% CH3CN; 0.1% TFA 10 min 
(2a) 73% H20: 27% CH3CN; 0.1% TFA 8.5 min 
77% H20; 23% CH3CN; 0.1% TFA 13.5 min 
(2b) 77% H20: 23% CH3CN; 0.1% TFA 16.5 min 
( 1 2) 77% H20; 23% CH3CN; 0.1% TFA 18.5 min 
( 1 3) 73% H20; 27% CH3CN; 0.1% TFA 6.5 min 
( 13b) 77% H20; 23% CH3CN; 0.1% TFA 19.5 min 
( 1 5) 77% H20: 23% CH3CN; 0.1% TFA 12.5 min 
( 15a) 77% H20: 23% CH3CN; 0.1% TFA 37 min 
( 1 7) 80% H20: 20% CH3CN; 0.1% TFA 10.5 min 
(20)d see below 58 min 
(22)d see below 53 min 
aunless otherwise noted, the column used for the analysis was a YMC 
ODS-AQ C18: 4.6 x 250 mmol at 1ml/min monitoring via UV detection at 
254 nm. 
bRetention times cited are approximate. 
ccolumn used for the analysis was a YMC Basic C1a: 4.6 x 250 mm 
at 1 ml/min monitoring via RI and UV detection at 220 nm. Solvent 
system: 35% H20; 32.5% MeOH; 32.5% CH3CN; 3.6g/l K2HP04; 
12mUL ethylene glycol. 
dcolumn used for the analysis was a Vydac 214TP54 Ca column. A 
gradient was employed with A=H20; 0.1% TFA; B=70%CH3CN; 30% 
H20; 0.1% TFA. 
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The fractions were eluted at a rate of around 5 ml/15 min. The first blue 
band was eluted at fraction 5-7, combined, and lyophilized to give a very 
small amount of material. The second blue band was eluted at fractions 
10-12 and was found to contain unreacted iodoacetamide. The Nmr of 
the first band showed some encouraging results although solvent 
suppression techniques will have to be used to obtain a reasonable 1 H 
and 13c Nmr spectra 125, 126.128-130_ Thyrocalcitonin does not absorb 
strongly in the UV at 254 nm. Hplc (UV detection at 254 nm) of the 
reaction was difficult to interpret because of the small amount of material 
available and detection limitations (Table 12). However, during the 
course of the investigation, a Hewlett Packard (1040A) diode array 
multiple wavelength detector was donated to our project. Additionally, a 
Beckman (11 OB) multiple delivery system became available for our use. 
With this added technology, it would be possible to run an hplc sample at 
several wavelengths simultaneously as well a run a program employed 
gadient system. Hplc analysis was conducted on the remainder of the 
sample using the following gradient parameters; A=H20; 0.1 % TF A; 
B=70%CH3CN; 30% H20; 0.1% TFA;40-80% B over 35 min;80-40% B 
over 25 min. at a flow rate of 1.2 mUmin. The column used for the 
analysis was a Vydac 214TP54 Ce column and the wavelengths 
monitored included 225, 254 and 600 nm. Using these parameters, the 
Bovine thyrocalcitonin adduct appears to have a retention time of about 
52 min. The peak is broad and absorbs at both the 225 and 600 nm 
wavelengths. 
l, ..... ..........,,.~::J,_v ... c. • ......,.,,..,\ 
rrs..-<>i-A.,,.-lti.-T,,_~ ........... ,J.'P 
Me...Oly-Phe-Gl}'-Pro-Olu-Tlni-Pro-NH2 
(19) 
+ DTT/Urea 
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H ~N~ 
r~N-v/' ~~s~N(C~)2 
0 Cl-b r 
( 1 3) 
H ~N~ 
/lfN-v/'~~s~N(C~)2 
r 0 Cfj, r 
Cys-Ser-!'\sn-Le-s~~ys-Val-Le--:;ei"""Ala.-:f~ 
rrs..-i'bo-A .......... T~,....,. ........... ,, .. t, 
Met-Gt~Pti.-Gl)>-Prcr"Gh.i-'rm-Pm-NHt2 
(20) 
Scheme 21 
Since the supply of Bovine thyrocalcitonin was exhausted, no further 
chemical studies could be conducted on this sample. 
C. The synthesis of Rat thyrocalcitonin conjugate (22) 
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Rat thyrocalcitonin differs from Human thyrocalcitonin by 2 
amino acid residues. The Rat thyrocalcitonin (0.25 mg) that was used for 
this experiment was donated to us from Loyola University Medical 
School. The sample itself was sold by Sigma (0.25 mg; $125.45) as a 
lyophilized powder (97% minimum via hplc). The preparation of rat 
thyrocalcitonin conjugate (22) was initiated according to a literature 
procedure 111. According to this procedure, 8 M urea was used as a 
denaturant. Rat Thyrocalcitonin (21) (0.25 mg; 0.07 µ.mol; 1 eq) was 
dissolved in 0.1 ml Tris buffer and slowly stirred in a covered, nitrogen 
flushed, flask at ambient temperature. Urea (0.1 ml; 8 M) was added to 
this solution. Dithiothreitol (OTT) (0.13 mg; 10 eq) was dissolved in 0.1 
ml Tris buffer and this solution was added dropwise to the 
thyrocalcitonin slurry. N-aminoethyl-2-iodoethanamide Azure B (13) (0.3 
mg; 10 eq) was dissolved in 0.1 ml Tris buffer at pH 8.5 and this solution 
was slowly added to the thyrocalcitonin solution over the course of 1 min. 
The reaction was stirred at RT under nitrogen for 18 h. The reaction was 
quenched with 10% HCI until the pH of the reaction was 2-3. 
8 1 
Table 12 
Hplc traces for (19) and (20)a,b 
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aHplc analysis was conducted using the following gradient parameters; 
A=H20: 0.1% TFA: B=70%CH3CN: 30% H20; 0.1% TFA;40-80% B over 
35 min;80-40% B over 25 min. at a flow rate of 1.2 mUmin. The column 
used for the analysis was a Vydac 214TP54 Ca column and the 
wavelengths monitored included 225, 254 and 600 nm. . 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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The reaction was extracted with EtOAc to remove any unreacted OTT . 
The reaction mixture was lyophilized to a blue solid. The residue was 
purified on a 1x20 cm column using Biogel-P (fine) (Bio-Rad) and 0.1 M 
acetic acid as eluent. The Biogel-P was prepared according to Bio-Rad 
instructions. The buffer chosen for the elution was 0.1 M acetic acid. 
This buffer was chosen because of its use in a paper dealing with the 
purification of porcine thyrocalcitonin 11 o. The buffer was prepared 
according to a literature procedure 127. The fractions were eluted at a 
rate of around 5 mU15 min. The blue band was retained at the top of the 
column. MeOH was added to the buffer in order to elute this band. This 
band was collected after eluting 10 ml of 3;2 mixture of MeOH ;water. 
The residue was concentrated down to a blue powder using high 
vacuum. Since the supply of Rat thyrocalcitonin was exhausted, the 
experiment was not duplicated. Hplc analysis was conducted on the 
remainder of the sample using the following gradient parameters; 
A=H20; 0.1% TFA; B=70%CH3CN; 30% H20; 0.1% TFA;40-80% B over 
35 min;80-40% B over 25 min. at a flow rate of 1.2 mUmin. The column 
used for the analysis was a Vydac 214TP54 Ca column and the 
wavelengths monitored included 230, 254 and 600 nm. Using these 
parameters, the Rat thyrocalcitonin adduct appears to have a retention 
time of about 54 min. The peak is broad and absorbs at both the 230 and 
600 nm wavelengths. 
Table 13 
UV/Vis Data for Significant Compoundsa 
compound A. max rb 
Azure B 640 33,986 
(2a) 583 30,546 
(2b) 635 32,670 
(7) 651 42.000 
( 1 2) 625 23, 110 
( 13)3 615 20,706 
( 13a) 617 40,690 
( 13b) 606 24,685 
( 1 5) 633 17' 500 
( 15a) 622 35,500 
( 1 7) 595 34,937 
(20)4 585 35,876 
(22) 603 37,895 
aunless otherwise noted, UV spectra were recorded using a Beckman 
DU-40 spectrophotometer and MeOH was used as the solvent. 
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br were calculated using the Beer-Lambert Alie formula where I = 1 cni; 
A = Absorbance at A. max; c = moles/L. 
3M ethylene chloride/Meo H solvent 
4o2o solvent 
L,,... ......... ....&::J,......_1--GirU.-Tl 
rft" Pm-Ph-Tin-+liir-Phr L~sn-1..eu-Asp.-Gln..:rhr 
ThP-SeP-Ile--Oly ~ a>-<Jly-i'Ua.-Pro-NH2 
(21) 
+ DTT/Urea 
H ~N~ 
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1~Nv""~~s~N(C~)2 
0 Cf-b r 
( 1 3) 
H ~N~ 
/'if Nv"" ~~s~N(C~)2 
ls o Cl-b r y-'Jly-Asn-Le-Sei-:l'hr-€~eP-Le~l~~T\ 
f "'"""'° "'-~,..Pho-L,.. Am.L.-A>p-Oh,..J. 
Tur Se,_11 .. Gly-Val .. Oly-Ala~ro .:WH 2 
(22) 
Scheme 22 
I I, 
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Table 14 
Hplc traces for (21) and (22)a.b 
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aHplc analysis was conducted using the following gradient parameters; 
A=H20; 0.1% TFA; B=70%CH3CN; 30% H20; 0.1% TFA;40-80% B over 
35 min;80-40% B over 25 min. at a flow rate of 1.2 ml/min. The column 
used for the analysis was a Vydac 214TP54 Cs column and the 
wavelengths monitored included 225, 254 and 600 nm. 
b Retention times cited are approximate due to fluctuations in column 
pressure. It is recommended that compounds be restandardized and 
distances measured as a function of identity rather than absolute 
retention ti mes. 
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Table 15 
Approximate yields from selected reactions 
Reaction yields 
Azure B to (2a) 40% 
Azure B to (7) 60% 
(2a) to (2b) 35% 
(12) to (13) 15% 
(2a) to (13) (NHSIAA derived) 58% 
(13) (NHSIAA derived) to (1 5) 15% 
(15) (NHSIAA derived) to (17) 10% 
(13a) to (13b) (NHSIAA derived) 37% 
(13b) to (15a) (NHSIAA derived) 23% 
Table 16 
Comparison of UV /Vis Data of 2nd generation PDT drug 
candidates and compounds (20) and (22) 
compound 
Photofrin 118* 
Kryptocyani ne46* 
Merocyanine 54013,45* 
Nile Blue A66,69* 
Nile Blue A-6-lodide66,69* 
NBA61odoTetHyd66,69* 
(20) 
(22) 
Azure B 
Azure A66* 
Methylene Blue41* 
asolvent and pH dependent 
bp H de pen dent 
*see Bibliography 
A. max ra 
630 5000 
704 212,000 
540 40,000 
632 65,800 
660 ----
637 70,000 
585 35,876 
603 37 ,895 
640 33,986 
623 66,000 
661 88,000 
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<1>102b 
0.25 
v low 
0.19 
0.05 
0.281 
0.857 
TBD 
TBD 
0.41 
0.385 
0.443 
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Summary 
The objective of this project was to prepare novel 
derivatives of Azure B for eventual use in biological studies. In order to 
do this, synthetic chemistry was used to build structural specificity on to 
Azure B via a linker and a receptor specific peptide chain. In particular, 
we proposed to construct a dye peptide conjugate where the 
photosensitizer was Azure B. The terminal secondary amino group of 
Azure B would then react with an activated linker. This goal was realized 
with the successful preparation of (2), (12), and (13). The activated end 
of the dye-linker was reacted with Cysteine, a Pentapeptide, Bovine 
thyrocalcitonin and Rat thyrocalcitonin, to give dye peptide conjugates. 
In addition, this synthetic strategy was extended to create derivatives of 
Azure A . During the course of this investigation, a novel preparation of 
Methylene Blue was discovered using Azure B as the starting material. 
As a follow-up to the synthetic chemistry, radionuclide and related 
biological studies should be performed to test the biological theory that 
lead to the formulation of the related chemistry. If these compounds are 
found to be biologically significant, the chemistry presented in this 
dissertation, could lead to better understanding of the SAR profile of 
calcitonin and its use clinically in adult humans. 
CHAPTER Ill 
EXPERIMENTAL 
Unless otherwise noted, materials were obtained from commercial 
suppliers and used without further purification. Melting points were taken 
in a Thomas-Hoover capillary apparatus and were uncorrected. 
Elemental analyses were obtained for some of the new compounds 
reported. Some elemental analyses were performed by the Oneida 
Research Services, Inc, while others were performed by Midwest 
Microlab. Some Ir, Nmr, and Mass spectra were recorded by the Abbott 
structural chemistry department. E Merck silica gel (70-230 mesh) 
obtained from VWR Scientific was used for column chromatogaphy. Bio-
Gel P (Fine 45-90 µ.m) was used for some column chromatography. 
Preparative chromatography was performed on selected examples using 
a 20x20 60F-254 Merck preparative plate in accordance with the 
following standard procedure: the sample was loaded onto the plate 
using 0.5-1.0 ml methylene chloride/methanol (3:2) and the dried plate 
was immersed in 100 ml of a mobile phase, the plate was run to 1 cm 
from the top, thoroughly dried and the UV(+) bands were carefully 
extracted using a single edged razor blade. The silica was crushed with 
89 
90 
a mortar and pestle and immersed in a 50/50 mixture of methanol/ethyl 
acetate for 1 h, gravity filtered and concentrated. After purification, all of 
the dye activated linker compounds were concentrated in acid washed 
glassware or a few drops of 10% HCI was added to the eluent to ensure 
salt formation of the compound. Analytical HPlCs (YMC ODS-AQ C1 a; 
4.6x250 mm; 70-80% H20; 30-20% CH3CN; 0.1% trifluoroacetic acid) 
were run in order to monitor reaction progress and establish standard 
elution times using UV detection at 254 nm unless otherwise noted. Hplc 
analysis on the thyrocalcitonin samples were conducted using the 
following gradient parameters; A=H20; 0.1% TFA; B=70%CH3CN; 30% 
H20; 0.1% TFA;40-80% B over 35 min;80-40% B over 25 min. at a flow 
rate of 1.2 ml/min. The column used for the analysis was a Vydac 
214TP54 Ca column and the wavelengths monitored included 225, 254 
and 600 nm. .Preparative hplcs were run using a Ranin Dynamax semi-
preparative column (C1a; 21.4x250 mm; 70-80% H20; 30-20% CH3CN; 
0.1 % trifluoroacetic acid) in order to obtain pure product samples. Ceric 
sulfate stain (1800 ml H20; 200 ml H2S04; 50 g ammonium molybate; 
20 g eerie sulfate) and ninhydrin (500 mg ninhydrin; 500 ml 95% EtOH) 
were used to stain all tic plates of non-dye products 
Some Nmr spectra were determined on a General Electric GN-300 
spectrometer operating at 300.1 MHz while others were determined by a 
Varian spectrometer operating at 300.1 MHz. Chemical shifts were 
9 1 
expressed in ppm downfield from internal tetramethylsilane. Significant 
1 H Nmr data were tabulated in the order: multiplicity (s. singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet; b, broad, ex, exchangeable with 
D20), number of protons, designation and coupling constants where 
applicable. 13c Nmr spectra were all proton-decoupled and some 
carbons were assigned using DEPT experiments. Most of the 13c Nmr 
spectra were predicted using the ACD/Nmr computer program sold by 
Advanced Chemistry Development. Toronto, Canada. The IR spectra 
were recorded on a Perkin-Elmer Model 71 OA infrared spectrometer. 
UV /Vis spectra were recorded on a Beckman D U-40 spectrophotometer. 
Some mass spectra were obtained with a Hewlett-Packard 5985A mass 
spectrometer or a Kratos Ms-50 with El source (70eV) while others were 
analyzed by the analytical services lab of Northwestern University. All 
solvents and reagents were purified when necessary according to 
standard literature methods. Air- or water-sensitive reactions were 
conducted under nitrogen atmosphere utilizing standard techniques. 
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The synthesis of compounds 
1. N-t-Butyloxycarbonyl-2-chloroethylamine ( 1) 
Sodium chloride (1.2 g; 3.2 eq; 19 mmol) and sodium bicarbonate 
(0.54 g; 1 eq; 6 mmol) were dissolved in water (7.5 ml) and set aside. 
DH-Butyl dicarbonate (1.09 g; 0.8 eq; 5 mmol) and 
2-chloroethylamine (0.69 g; 1 eq; 6 mmol) were added to an oven dried, 
round bottom flask containing 10 ml of rapidly stirring chloroform. The 
reserved salt solution was added to the chloroform solution and the 
heterogeneous mixture was stirred at RT for 5-10 min and then heated to 
85 oc and refluxed for 3 hours. The reaction was judged complete via tic 
analysis and the clear solution was poured into a separatory funnel 
containing 100 ml methylene chloride and 50 ml of 5% NaHC03. The 
aqueous phase was washed with 3x20 ml portions of methylene 
chloride and the organic extracts were combined, washed with brine and 
dried with anhydrous Na2S04. The organic phase was gravity filtered 
and the solvent was evaporated 1/7 vacuo to give 0. 74 g yellow oil. The 
residue oil was fractionally distilled at 30 m Bar between 107 oc and 
11 O oc to give 0.35 g colorless liquid. Procedure yields 48% after 
distillation. Rf=0.64 (toluene:methanol 10:1 ml). 1 H-NMR (CD30D): ~ 
4.9 (m ,1H), 3.55 (m, 2H), 3.35 (m, 2H), 1.45 (s, 9H). 13c-NMR (CD30D): 
& 155, 79, 42.0 (CH2N), 41.7 (CH2CI) 29.5. I A (film): 3450-3300, 3000-
2950, 1725-1690(s), 1520, 1463, 1245, 1175 cm-1. Mass spectrum 
(FAB/Mat 95/G/MeOH): m/e 197 (m+18). 
2a. N-2-aminoethyl Azure B (2) 
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Azure B (0.13 g; 0.4 mmol) was dissolved in 2 ml of anhydrous 
DMF. 2-(N-Carbobenzyloxyamino)-ethyl-2-methane sulfonate (11) (0.15 
g ; 1.4 eq; 0.75 mmol) was dissolved in 1.0 ml of DMF and set aside. 
Sodium hydride (80% dispersion in mineral oil) (0.063 g; 7 eq; 2.7 mmol) 
was added portionwise to the stirring blue solution. The resulting deep 
purple solution was stirred at RT for 15 min. 2-(N-
Carbobenzyloxyamino)-ethyl-2-methane sultanate (11) solution was 
added dropwise to the Azure B reaction mixture and this was stirred at 
ambient temperature and monitored via tic and hplc. At 15 min, hplc 
showed all Azure B was consumed and a less polar and more polar 
product formed. In 1.5 h, the less polar product reacted near exclusively 
to the more polar product. The violet solution was evaporated iil vacuo 
(5-6 days) to give a blue residue. The residue was dissolved in a MeOH 
and loaded on to a hplc semi-preparative column affording 42 mg of (2) 
in 20% yield. 
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2b. N-2-ammonium ethyl Azure B (2a) 
Azure B (1 g; 3.3 mmol) was dissolved in 10 ml of anhydrous THF. 
2-(N-Carbobenzyloxyamino)-ethyl-2-methane sulfonate (11) (1.2g; 1.3 
eq; 4.26 mmol) was dissolved in 6 ml of THF and set aside. Sodium 
hydride (80% dispersion in mineral oil) (0.5 g; 6.6 eq; 21 mmol) was 
added portionwise to the stirring blue solution. The resulting deep 
purple-red solution was stirred at RT for 1.5 h. 2-(N-
Carbobenzyloxyamino)-ethyl-2-methane sulfonate (11) solution was 
added dropwise to the Azure B reaction mixture and this was stirred at 
ambient temperature and monitored via tic and hplc. At 36 h, hplc 
showed 85% Azure B was consumed and a less polar and more polar 
product formed. The violet solution was carefully acidified with 2 ml 10% 
HCI and evaporated 1i? vacuo to give a blue residue. The residue was 
dissolved in a MeOH and loaded on to a silica gel column 
(CH2Cl2:MeOH (10: 1.5)) that contained pre-treated silica gel (ethanol: 
ammonium hydroxide (3:1)) giving (2) in 40% yield. m.p. 132-1350 C; 
Rf=0.29 (methylene chloride:methanol 10:1.4 ml); pre-treated (ethanol: 
ammonium hydroxide 3:1 ml). 1 H-NMR (CD30D): S 7.9 (m, 2H), 7.5-7.1 
(m, 4H), 3.65 (m, 1H), 3.4 (m, 1H), 3.4 (s, 6H), 3.3 (m, 1H), 2.7 (s, 3H). 
13c-NMR (CD30D): S 158.3, 155.8, 140, 139-135, 122, 113, 108, 107, 
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79, 47, 41, 39. UV/Vis 583 nm (£=30, 546). IR (KBr.): 3450-3300, 3000-
2950, 1690, 1200, 1150 cm-1. Mass spectrum (FAB/mNBA): m/e 313 
(m+1). 
2c. N-Carbobenzyloxy-amino-ethyl Azure B (2b) 
N-ammonium ethyl Azure B (2a) (0.040 g; 0.13 mmol) was 
dissolved in a mixture of 1 ml methylene chloride and 1 ml MeOH. This 
was stirred at ambient temperature under nitrogen. DMAP (0.015 g; 1 
eq) was added to the mixture followed by NCbzNHS (0.048 g; 1.5 eq). 
The resulting mixture was stirred at room temperature under nitrogen for 
24 h. At 24 h, tic showed 85% complete reaction to a less polar product. 
The dark purple reaction mixture was quenched by evaporating the 
solvent and the resulting solid was diluted with the minimum amount 
methylene chloride/MeOH and loaded on to a preparative tic plate and 
isolated according to standard procedures. Procedure gives (2b) in 35% 
yield. Rf=0.35 (methylene chloride:methanol 10:1.5 ml). 1 H-NMR 
(CD30D): 8 8.05-6.8 (m, 11 H), 4.7 (m, 2H), 3.7 (s, 1 H), 3.3 (s, 6H), 3.15 
(s, 2H), 3.02 (s, 3H). 13c-NMR (CD30D): 8 158.6, 143, 139-121, 105, 
80, 61, 42, 31. UV/Vis 625 nm (£=32,670). IR (.CD30D sol'n): 3450-
3300, 3000-2950, 1656-54, 1540, 1449, 1025 cm-1. 
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3. N-Carbobenzyloxy-ethanolamine (3) 
C arbobenzyl oxy-N-hydroxy-su cc in i mi de ( 24 g; 98. 2 mm ol). a trace 
amount DMAP, and 50 ml anhydrous methylene chloride were 
combined in an oven dried 100 ml flask. This solution was stirred at RT 
for 3 min. Ethanolamine (4. 94 ml; 1 eq; 82 mmol) was added to the 
solution and the mixture was stirred at RT. After the ethanolamine was 
added, a white slurry began to form in the reaction vessel. In 2 h, the 
white slurry dissolved to form a clear solution. After 18 h, the reaction 
was analyzed by tic and was shown to be complete. The clear solution 
was poured into a separatory funnel containing 100 ml methylene 
chloride and 50 ml of 5% NaHC03. The organic phase was washed 
with 50 ml 10% phosphate buffer and rewashed with 50 ml of 5% 
NaHC03. The organic washes were combined, extracted with brine and 
dried with anhydrous Na2S04. The organic phase was gravity filtered 
and the solvent was evaporated 11? vacuo to give 23.7 g white solid. The 
white solid was dissolved in the minimum amount of hot ethyl acetate 
and placed in a -25 oc freezer overnight. The solid was suction filtered 
with cold ethyl acetate and the residue crystals were dried 1/7 vacuo 
giving 1 O g of desired material in 64% yield. Rf=0.158 (hexane:ethyl 
acetate 2:1 ml). m.p. 65.1 oc 1 H-NMR (CDCl3): 8 7.45-7.3 (m, 5H), 5.2 
(s, 1 H), 5.1 (s, 2H), 3. 7 (m 2H), 3.35(m, 2H), (2.25 (s, 1 H). 13C-NMR 
97 
(CDCl3): ~ 157, 136, 120, 129-128, 67 (CH20), 62 (CH20), 43.5 
(CH20). IR (KBr): 3300, 3000, 1690, 1545. 1270 cm-1. Mass spectrum 
(DCl/NH3): m/e 213 (m+17), 196 (m+1). Anal. Calcd C10H13N03 
(195.22): %C 61.53, %H 6.71, %N 7.17; Found %C 61.09, %H 6.68, %N 
7.15. 
4. N-Carbobenzyloxyaminomethanal (4) 2-(N-
Carbobenzyloxy amino)-ethanal (5)and N-
Carbobenzyloxy-methanolamine-N-2-
aminoethanoate (6) 
N-Carbobenzyloxy-ethanolamine (3) ( 4. 9 g; 25.1 mmol) was 
dissolved in methylene chloride and stirred at RT under nitrogen. 
Pyridinium chlorochromate (PCC) (5.6 g; 25.9 mmol) was added 
portionwise to the substrate solution and this mixture was stirred at RT for 
2 h. The reaction mixture turned orange yellow in color. After 2 h. tic 
analysis showed the reaction to be around 80% complete with the 
formation of two major non-polar products. More PCC (1. 5 g; 6. 95 mmol) 
was added to the reaction in order to drive it to completion. The reaction 
was stirred for 24 h at RT. After 24 h, tic analysis showed the reaction to 
be around 100% complete to a least two major non-polar products. The 
brown reaction mixture was quenched by pouring diethyl ether into the 
reaction flask and stirring at RT. The resulting slurry was filtered using a 
millipore filtration apparatus. The ether layers were combined and 
concentrated 1iJ vacuo to give 4 g of a yellow-brown oil. The crude oil 
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was purified via chromatography on a silica gel gravity column (solvent 
system composed of hexane:ethyl acetate; 2:1 ml) affording 1.87 g of 
clear, odorless oil of (4) 50 mg of a mixture of (5) and 1.45 g of (6). (4) 
m.p. 51. 7-53.1 oc. Af=0.57 (hexane:ethyl acetate 2:1 ml). 1 H-NMA 
(CDCl3): S 9.0-8. 9 (m, 1 H), 7. 7 (s, 1 H), 7.3 (m, 5H, aromatic), 5.25 (s, 
2H). 13C-NMA (COCl3): S 164, 152.5, 134.5, 128.5-127, 68.5(CH20). 
IA (KBr): 3460, 3280, 3000-2880, 1740, 1695, 1490, 1245, 1210cm-1. 
Mass spectrum (OCl/NH3): m/e 197 (m+17), 180 (m+1). Anal. Calcd for 
C9H9N03 (179.176): 60.33 %C, 5.06 %H, 7.82 %N; Found 59.95 %C, 
4.87 %H, 7.53 %N. (6) m.p. 63-68 oc. Af=0.13 (hexane:ethyl acetate 2:1 
ml).1H-NMA (CDCl3): S 7.4-7.18 (m, 5H, aromatic), 5.25 (m, 2H), 4.25 
(m, 2H), 3.95 (m, 2H), 3.45 (m, 1H). 13C-NMA (CDCl3): 8170, 156.3, 
136.1, 128.5-128, 67.3(CH20), 67.3(CH20), 64.5(CH20), 43(CH20), 
40(CH20). IA (KBr): 3460, 3280, 3000-2880, 1740, 1695, 1535, 1490, 
1245, 1210 cm-1. Mass spectrum (DCl/NH3): m/e 404 (m+17), 388 
(m+1). Anal. Calcd for C20H2205N2 (386.408): 62.17 %C, 5.74 %H, 
7.25 %N;; Found 62.16 %C, 5. 77 %H 7.09 %N; 
General Procedure for addition of aldehydes to Azure B 
Azure B (0.5 g; 1.64 mmol, 1.0 eq) was added to a 25 ml round 
bottom flask containing 1 5.0 ml anhydrous methanol under N2. 
Aldehyde (1.5 eq.) was added portionwise to the Azure B solution. 
... 
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Glacial acetic acid (0.1 ml; 1 .0 eq) was added dropwise to the blue 
solution. Sodium cyanoborohydride (0.18 g; 2.95 mmol; 1.8 eq) was 
added to the blue solution. The reaction mixture was stirred at 80 oc for 
18 h. The reaction progress was monitored via reverse phase hplc. The 
reaction mixture was concentrated iil vacuo to give a crude oil. The 
crude oil was purified via preparative hplc. 
5. Methylene Blue (7). The reaction with formalin. 
Procedure gives (7) in 60% yield. Rf=0.37 (methylene 
chloride:methanol 10:1.4 ml). 1 H-NMR (CD30D): 8 7. 9-7.93 (m. 2H), 
7.55-7.37 (m, 3H), 4.25 (m, 2H), 3.95 (m, 2H), 3.45 (s, 12H). 13C-NMR 
(CD30D): 8 156.3, 139.1, 136.5-135.5, 120, 107.1, 41.5. UV/Vis 651 nm 
(E=42,000). IR (KBr): 3450-3300, 3000-2950, 1690, 1200, 1150 cm-1. 
Mass spectrum (DCl/NH3): m/e 300 (m+17), 286 (m+1). 
6. N-t-Butyloxycarbonyl-ethanolamine ( 8) 
Ethanolamine (5 g; 82 mmol) was dissolved in 50 ml of 
anhydrous methylene chloride and stirred at ambient temperature. 
N-t-butyl-succinimide carbonate (21 g; 98 mmol) and a trace amount 
DMAP were added to the ethanoamine solution. After the mixture was 
combined, a white slurry began to form in the reaction vessel. After 18 h, 
the reaction was analyzed by tic and was shown to be 80% complete. 
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The clear solution was poured into a separatory funnel containing 100 
ml methylene chloride and 50 ml of 5% NaHC03. The organic phase 
was washed with 50 ml 10% phosphate buffer and rewashed with 50 ml 
of 5% NaHC03. The organic washes were combined, extracted with 
brine and dried with anhydrous Na2S04. The organic phase was gravity 
filtered and the solvent was evaporated ti? vacuo to give 5.2 g colorless 
oil. The residue was dissolved in the minimum amount of 
hexane/CH2Cl2 and loaded on to a silica gel gravity column (solvent 
system composed of hexane/EtOAc/CH2Cl2 6:3:1 ml) affording 2.6 g (8) 
in 49% yield. Ninhydrin Rf=0.178 (hexane:ethyl acetate 2:1 ml). 1 H-
NMR (CDCl3): 8 4.9 (s, 1 H), 3.71 (m, 2H), 3.30 (m, 2H), 1.45 (s, 9H). 
13C-NMR (CDCl3): 8 157, 79.5, 62.3 (CH20), 43 (CH20), 28.2 (CH20). 
IR (Film): 3450-3300, 3000, 1690, 1535, 1170 cm-1. Mass spectrum 
(DCl/NH3): m/e 179 (m+17), 162 (m+1). Anal. Calcd C7H15N03 
(161.2025): %C 52.16, %H 9.38, %N 8.69; Found %C 52.06, %H 9.35, 
%N 8.38. 
7. 2-( N-t-Butyloxycarbonylamino)-ethyl-2-methane sulfonate 
(9) 
N-t-Butyloxycarbonyl-ethanolamine (8) (1 g; 1.28 mmol) was 
dissolved in 24 ml pyridine and stirred at RT under nitrogen. 
Methanesulfonyl chloride (0.59 ml; 1.2 eq; 1.6 mmol) was added 
1 0 1 
dropwise to the substrate solution and this mixture was stirred at RT for 
24 h. The reaction mixture turned a golden yellow in color. After 24 h, tic 
analysis (via mini-workup: see results and discussion section) showed 
complete reaction to a less polar product. The reaction was quenched by 
pouring the reaction mixture into a separatory flask containing 200 ml 
methylene chloride and washing the organic layer with saturated CuS04 
solution. The organic layer was backwashed 2x with 100 ml portions of 
saturated CuS04 solution and the organic washes were dried over 
anhydrous Na2S04. The organic phase was gravity filtered and the 
solvent was evaporated in vacuoto give a brown oil. The residue was 
dissolved in the minimum amount of hexane/CH2Cl2 and loaded on to a 
silica gel gravity column (solvent system composed of hexane/CH2Cl2 
10:5 ml) affording (9) in 45% yield. Rf=0.168 (hexane:ethyl acetate 2:1 
ml. Ninhydrin Rt=0.38 (hexane:ethyl acetate 2:1 ml). m.p. 85. 7-90.1 
oc. 1 H-NMR (CDCl3): & 4.9 (s, 1 H), 4.31 (m, 2H), 3.47 (m, 2H), 3.05 (s, 
3H), 1.45 (s, 9H). 13C-NMR (CDCl3): & 155, 79.5, 68. 5, 40.1, 37. 5 
(CH20), 28.2 (CH20). IA (MeOH sol'n): 3450-3300, 3000, 1745, 1350, 
121 o. 1190, 1175 cm-1. Mass spectrum (OCl/NH3): m/e 257 (m+17), 
239 (m+1 ). 
8. 2-(N-Carbobenzyloxyamino)-ethyl-2-methane sulfonate 
( 11) 
N-Carbobenzyloxy-ethanolamine (3) (8 g; 41 mmol) was 
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dissolved in methylene chloride and stirred at RT under nitrogen. 4-
Dimethylaminopyridine (5.56 g; 49 mmol) was added all at once to the 
stirring methylene chloride solution. Methanesulfonyl chloride (4.74 ml; 
61 mmol) was added dropwise to the substrate solution and this mixture 
was stirred at RT for 36 h. After 36 h, tic analysis (via mini-workup: see 
results and discussion section) showed complete reaction to a less polar 
product. The reaction was quenched by pouring the reaction mixture into 
a separatory funnel containing 100 ml brine and 100 ml sat'd KH2P04. 
The methylene chloride layer was backwashed 2x with 100 ml of 
saturated NaHC03 solution and the organic extracts were dried over 
anhydrous Na2S04. The organic phase was gravity filtered and the 
solvent was evaporated 1n vacuo to give a clear oil that solidified upon 
standing. The residue was dissolved in the minimum amount of 
hexane/CH2Cl2 and loaded on to a silica gel gravity column (solvent 
system composed of hexane/CH2Cl2 10:5 ml) affording 9.4 g (11) in 
84% yield Rf=0.168 (hexane:ethyl acetate 2:1 ml). m.p. 62. 7 oc. 1 H-
NMR (CDCl3): '5 7.4-7.35 (m, 5H), 5.17 (s, 3H), 4.30 (m, 2H), 3.55 (m, 
2H), 3.0 (s, 3H). 13C-NMR (CDCl3): '5 156.3, 136, 129-128, 68.5 
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(CH20), 67 (CH20), 37. 5 (CH20). IR (KBr): 3265, 1685, 1540, 1350, 
1257, 1170 cm-1. Mass spectrum. (DCl/NH3): 291 (m+17), m/e 274 
(m+1 ). Anal. Cale for C11H1505SN (273.30): %C 48.34, %H 5.53, %N 
5.12; Found %C 48.34, %H 5.57, %N 5.06. 
9. N-aminoethyl-2-chloroethanamide-Azure B ( 12) 
N-ammonium ethyl Azure B (crude 65%) (2a) (3.6 g; 1 eq; 11.5 
mmol) was slurried in 20 ml of THF (anhydrous) at ambient temperature 
under N2 and set aside. Chloroacetic acid (recrystallized from 
chloroform) (1 g; 11 mmol) was added to the 20 ml THF (anhydrous) 
followed by dicyclohexylcarbodiimide (DCC) (distilled) ( 3. 3 g; 17 mmol). 
The resulting white slurry was stirred for 45 min at ambient temperature. 
Hunig's base ( diisopropylethylamine) ( 19 ml; 11 m mol) was added to 
the substrate solution just prior to mixing with the DCC slurry. The free 
amine of substrate (2) was added dropwise to the stirring DCC slurry. 
The reaction was stirred 36 h at ambient temperature monitoring the 
reaction via hplc. The deep blue reaction mixture was quenched at 36 h 
by evaporating in vacuo and dissolving the residue in methylene 
chloride. The methylene chloride solution was filtered via suction 
filtration through a scintered glass funnel and the filtrate was evaporated 
1i7 vacuo to a dark blue solid. The resulting product was purified via 
column chromatography (CH2Cl2:MeOH (1 O: 1. 5)) to give 
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1.5 g (33% yield) of 85% N-aminoethyl-2-chloroethanamide-Azure B 
(12). An alternative workup procedure includes the filtration of solid 
residue, followed by pouring the filtrate into a separatory funnel 
containing chloroform and brine. The organic layer was then washed 
with 10% HCI. The aqueous and organic layers were separated and 
concentrated down iil vacuo. Procedure afforded (12) in a 15% yield. 
m.p. (decamp) 162-1660 C; Rf=0.49 (methylene chloride:methanol 10:1.5 
ml);. 1H-NMR (CD30D): 8 7.8 (m, 1H), 7.5-7.0 (m, 6H), 4.55 (m. 1H), 
4.0 (m, 1 H), 3.7-3.5 (m, 4H), 3.35 (s. 6H), 3.23 (s, 3H). 13c-NMR 
(CD30D): 8 160, 157, 142, 141, 138, 135, 131, 124, 121, 119, 110, 109, 
69, 57, 49, 45, 43. UV/Vis 625 nm (E=23,110). IR (film): 3450-3300, 
3000-2950, 1662, 1603, 1586, 1540, 1482, 1400 cm-1. Mass spectrum 
(FAB/mNBA): m/e 353 (m-HCI). 
1 Oa. N-aminoethyl-2-iodoethanamide-Azure B (13) 
N-aminoethyl-2-chloroethanamide-Azure B (12) (0.01 g; 1 eq; 
0.025 mmol) was dissolved in 0.5 ml of THF and 0.5 ml acetone at 
ambient temperature under N2. Sodium iodide (0.0082 g; 2.2 eq.) was 
added rapidly to the stirring substrate solution. The reaction was 
monitored via hplc. At 18 h, the reaction was complete with product 
eluding at 19-20 min and and side product eluding at 4-6 min. The 
resulting blue-green reaction mixture was concentrated down in vacuo, 
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while covered, to give a deep blue-violet solid. The N-aminoethyl-2-
iodoethanamide-Azure B (13) was purified via column chromatography 
(CH2Cl2:MeOH (1 O: 1. 5)) to give 0.08 g of N-aminoethyl-N-ethanamide-
Azure B iodide (13) in 15% yield. 
1 Ob. N-aminoethyl-2-iodoethanamide-Azure B (13) 
N-ammonium ethyl Azure B (2a) (0.02g; 1 eq; 0.06 mmol) 
was dissolved in 0. 5 ml MeOH (anhydrous) covered, and stirred at RT. 
Succinimidyl iodoacetate (Sigma) (0.023g; 1. 5eq) was dissolved in 0. 5 
ml chloroform (distilled over CaH2) and set aside. Hunig's base ( 11. 5 
µ,l; 1.2 eq) was added to the substrate solution. Succinimidyl 
iodoacetate was added dropwise to the substrate solution. The reaction 
was covered, nitrogen flushed, and stirred at RT for 24 hr. The reaction 
was analyzed via hplc and tic. The mixture was concentrated down in 
vacuo, while covered, to give a deep blue-violet solid. The N-
aminoethyl-2-iodoethanamide-Azure B (13) was purified via column 
chromatography (CH2Cl2:MeOH (10: 1.5)) to give 0.018 g of N-
aminoethyl-2-iodoethanamide-Azure B (13)in 58% yield. Rf=0.78 
(methylene chloride:methanol 10:1.5 ml). 1 H-NMR (C0300): 8 7.9-6.5 
(m, 7H), 4.5 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.3 (m, 6H) 2.6 (m, 3H), 2.3 
(m, 2H). 13c-NMR (C0300): 8 170, 161, 149, 145, 138, 132-131, 122-
121, 120, 115, 101, 73, 55, 52, 47, 43, 30. UV/Vis 615 nm (£=20,706). 
IR (film): 3450-3300, 3000-2950, 1670, 1654, 1648, 1640, 1603, 
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1490 cm-1. Mass spectrum (FAS/Glycerine): m/e 478, 431. 387, 303. 
11. N-iodoformamide-Azure A ( 13b) 
Azure A (upper bands) (0.028 g; 0.1 mmol), was added to a foil 
covered flask containing 0.5 ml of anhydrous chloroform and 0.5 ml 
anhydrous MeOH. This mixture was stirred under nitrogen at ambient 
temperature. Hunig's base (0.022 ml; 1.5 eq) was added to the dye and 
the mixture was stirred for 5 min. NHSIAA (0.027 mg; 1 eq) was added to 
the mixture and the reaction was stirred at ambient temperature for 18 h. 
The reaction mixture was quenched by evaporating to dryness. During 
this process no heat was employed to facilitate the evaporating process 
and the flask remained shielded from light by a foil covering. The residue 
was used immediately to synthesize (1 5a). Procedure afforded 17 mg of 
(13b) in 37% yield. Rf=0.21 (methylene chloride:methanol 10:1.5 ml); 
Rt=0.54 (methylene chloride:methanol 10:3.5 ml). 1 H-NMR (CD30D): 8 
8.35 (s. 1H) 7.9-7.1 (m, 5H), 3.5 (m, 1H), 3.56 (m, 1H), 3.0 (s, 2H). 13c-
NMR (CD30D): 8 166, 165, 160, 143, 136, 129, 126, 125, 121, 120, 118, 
112, 111, 64, 51, 47, 30. UV/Vis 606 nm (£=24,685). IA (CD30D sol'n): 
3450-3300, 3000-2950, 1944, 1604, 1648, 1540. 1603. 1180. 990 cm-1. 
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12. L-Cysteine methanoate (14) 
L-Cysteine (Sigma) (2 g; 1 eq; 16.5 mmol) was dissolved in 100 
ml of anhydrous MeOH. Tosic acid (3.9 g; 1.5 eq) was added to the 
reaction as the solution was stirred for 14 h. Tic showed the reaction to 
be 85% complete giving a single, faintly staining (ninhydrin), less polar 
product. The reaction mixture was quenched by concentrating down in 
vacuo to a white solid. The residue was recrystallized using the 
minimum amount of hot I PA to give 0. 5g of delicate, white crystals of L -
Cysteine methanoate (14) as the tosyl salt in 23% yield. m.p. 1490 C; 
Rf=0.59 (methylene chloride:methanol 10:1.4 ml); pre-treated (ethanol: 
ammonium hydroxide3:1 ml); ninhydrin. 1 H-NMR (CD30D): S 4.1 (m, 
1 H), 3.2 (m, 1 H), 2. 9 (m, 2H), 2.23 (s, 3H). 13c-NMR (CD30D): S 170, 
58, 23, 21. IR (MeOH soln): 2978-2905, 1745, 1646, 1652, 14.12, 1278, 
1243, 985, 887, 770 cm-1. Mass spectrum (FAB/Mat 95/G/MeOH): m/e. 
Anal. Calcd for C4H10N02SCI (171.6428): 27.99 %C, 5.87 %H 
8.16%N; Found: 27.95%C, 5.80%H, 8.20%N. 
13. N-aminoethyl-N-thioethanamide-L-Cysteine methanoate-
Azure B (15) 
Borate buffer (0.2 M) (38.1 g boric acid; 6.2 g borax) was prepared 
and deoxygenated (millipore filtration) to give a buffer with a pH of 8.9. 
TRIS buffer was prepared by titrating TRIS base (1 g; 165ml distilled, 
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deoxygenated water) with TRIS-HCI (1 g; 127 ml distilled, deoxygenated 
water) to give a buffer with a final pH of 8. 5. N-aminoethyl-2-
iodoethanamide-Azure B (13) (0.002 g; 1 eq; 4.16 µ.mol) was dissolved 
in 0.25 ml THF, covered, and set aside. L-Cysteine methanoate (14) 
(0.003 g; 5 eq.) was dissolved in 0.25 ml boric acid or TRIS buffer and 
slowly stirred in a covered flask at ambient temperature. N-aminoethyl-2-
iodoethanamide-Azure B (13) solution was added to the buffered 
solution over the course of 1 min. The reaction was stirred at ambient 
temperature for 18 h and the reaction was analyzed by hplc. In 18 h , 
85% of the starting material was consumed giving a slightly more polar 
product than starting material. The reaction mixture was concentrated 
down in vacuo to a blue solid. Procedure afforded (1 5) in 15% yield. 
Rf=0.58 (methylene chloride:methanol 10:1.5 ml). 1 H-NMR (CD30D): S 
8-6.6 (m, 6H), 4.5 (m, 4H), 3.6 (m, 4H), 3.4-2.9 (m, 12H). 13c-NMR 
(CD30D): S 173, 168, 165, 151, 143, 126, 125, 116, 108, 101, 78, 76, 71, 
68, 67, 62, 61, 56, 47, 39, 30. UV/Vis 633 nm (£=17500). IR (MeOH 
soln): 3240, 2974, 1745, 1652, 1646, 1604, 1476 cm-1. Mass spectrum 
(FAB/mNBA): m/e 524 (m+CI), 461 (m-28), 456 (m-33). 
14. N-thioformamide-L-Cysteine methanoate-Azure A (15a) 
N-iodoformamide-Azure A (13b) (0.001 g; 0.026 mmol) was 
dissolved in 0.5 ml DMF, covered and set aside. L-Cysteine methanoate 
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(14) (0.0027 g; 8.5 eq) was dissolved in 0.5 ml Tris HCI buffer and 
slowly stirred in a covered flask at ambient temperature. N-
iodomethamide-Azure A (13b) solution was added to the buffered 
solution over the course of 1 min. The reaction was stirred at ambient 
temperature for 3 h and the reaction was analyzed by hplc In 3 h, 25% of 
the starting material was consumed. At 24 h the reaction was 50% 
complete and at 48 h the reaction mixture was shown to be 90% 
complete to give two less polar products. The reaction mixture was 
concentrated in vacuo to a blue solid. As with the parent iodoacetamide, 
N-thioformamide-L-Cysteine methanoate-Azure A ( 1 5a) rapidly 
decomposes to Azure A upon standing in MeOH. Procedure afforded 
(1 5a) in 23% yield. Rf=0.23 (methylene chloride:methanol 10:1.5 ml): 
Rf=0.59 (methylene chloride:methanol 10:3.5 ml). 1 H-NMR (CD30D): tS 
8-5.(s, 1H), 8.0-7.1(m, 6H), 5.4(s, 1H),4.6(s, H), 3.8(m, 4H), 3.4(m, 2H), 
3.3 (s, 6H). 13c-NMR (CD30D): tS 169, 167, 151, 137, 135, 132, 128, 
122, 119, 118, 103, 79, 62, 60, 59, 52, 43, 36, 32. UV/Vis 622 nm 
(r=35,500). IR (CD30D sol'n): 3240-2974, 1814, 1706, 1454, 1118, 990 
cm-1. 
General Procedure for addition of SH terminus of peptides 
to N-aminoethyl-2-iodoethanamide-Azure B (13) 
11 0 
N-aminoethyl-2-iodoethanamide-Azure B (13) (0.00125 g; 0.07 
mmol, 1.0 eq.) was added to a foil wrapped, 5 ml round bottom flask 
containing 0.1 ml anhydrous DMF and was set aside. Peptide (1.5 eq.) 
was added to a foil wrapped, 5 ml round bottom flask containing 0.2 ml, 
pH 8.5, TRISbuffer. N-aminoethyl-2-iodoethanamide-Azure B (13) 
solution was added dropwise to the stirring peptide. The reaction was 
stirred at ambient temperature under nitrogen for 2-3 days and analyzed 
via hplc. The reaction was analyzed on a Vydac column 214TP54 (0.46 
x 25 cm) (5 µ. Ca column). Hplc analysis was conducted on the 
remainder of the sample using the following gradient parameters; 
A=H20; 0.1% TFA; B=70%CH3CN; 30% H20; 0.1% TFA;40-80% B over 
35 min;80-40% B over 25 min. at a flow rate of 1.2 ml/min. The 
wavelengths monitored included 230. 254 and 600 nm. Quenched 
reaction mixtures were purified via gel filtration chromatography using 
Bio-Gel P (fine) (Bio-Rad). The gel was prepared according to standard 
protocol. Acetic Acid (pH 3.0; 0.1 M) was used as the eluent. 
1 1 1 
15. The reaction with Cys-Phe-Met-Arg-Phr-NH2 to give (17). 
1 H-NMR (C0300): 7.9-7.0 (m, 13 H), 6.89-6.72 (m, 3 H), 4.28-
4.05 (m, 5 H), 3.15-2.78 (m, 21 H), 2.82-2.22 (m, 7 H), 1.84 (m, 3 H), 1.7-
1.3 (m, 3 H). S UV /Vis 595 nm (£=34,937). 
16. The reduction of cystine ( 18) 
Cystine (0.1 g; 0.4 mmol; 1 eq) was dissolved in 5 ml, pH 8.5, Tris 
buffer and the slurry was stirred at RT under nitrogen. Oithiothreitol (OTT) 
(0.25 g; 5 eq) was dissolved in 5 ml Tris buffer and this solution was 
added dropwise to the cystine slurry. After 2. 5 h, the reaction had turned 
clear and the reaction was quenched with 10% HCI until the pH of the 
reaction was 2-3. The reaction was extracted with EtOAc to remove any 
unreacted OTT and OTU. The aqueous layer was concentrated1/7 vacuo 
to a white solid. m.p. 218-221 o C; 1 H-NMR (020): S 4.2 (m, 1 H), 3.0 (m, 
2H). 13C-NMR (020): S 173, 65, 58. 27. 
17. Bovine thyrocalcitonin-Azure B conjugate (20) 
Bovine Thyrocalcitonin (19) (0.0017 g; 0.47µ.mol; 1 eq.) was 
dissolved in 0. 3 ml boric acid buffer or Tris buffer and slowly stirred in a 
covered, nitrogen flushed, flask at ambient temperature. Urea (0.4 ml; 8 
M) was added to this solution and stirred for 1 O -15 min. Oithiothreitol 
(OTT) (0.0013 g; 10 eq) was dissolved in 0.3 ml Tris buffer and this 
·-.• 
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solution was added dropwise to the thyrocalcitonin slurry. After 2.5 h, the 
reaction had turned clear. N-aminoethyl-2-iodoethanamide-Azure B (13) 
(0.003 g; 12 eq) was dissolved in 0.1 ml Tris buffer at pH 8. 5 and this 
solution was slowly added to the thyrocalcitonin solution over the course 
of 1 min. The reaction was stirred at RT under nitrogen for 18 h. The 
reaction was quenched with 10% HCI until the pH of the reaction was 2-
3. The reaction was extracted with EtOAc to remove any unreacted DTI 
and DTU. The reaction mixture was lyophilized to a blue solid. The 
residue was purified on a 0.5x20 cm column using Biogel-P (fine) (Bio-
Rad) and 0.1 M acetic acid as eluent. The Biogel-P was prepared 
according to Bio-Rad instructions. The buffer chosen for the elution was 
0. 1 M acetic acid. This buff er was chosen because of its use in a paper 
dealing with the purificaton of porcine thyrocalcitonin 110. The buffer 
prepared according to a literature procedure 127. 
UV/Vis 585 nm (r=35,876). 
18. Rat thyrocalcitonin-Azure B conjugate (22) 
Rat Thyrocalcitonin (21) (0.25 mg; 1 eq; 0.07 µ.mol) was dissolved 
in 0.1 ml Tris buffer and slowly stirred in a covered, nitrogen flushed, 
flask at ambient temperature. Urea (0.1 ml; 8 M) was added to this 
solution. Dithiothreitol (DTI) (0.13 mg; 1 O eq) was dissolved in 0.1 ml 
Tris buffer and this solution was added dropwise to the thyrocalcitonin 
1 1 3 
slurry. N-aminoethyl-2-iodoethanamide-Azure B (13) (0.3 mg; 1 O eq) 
was dissolved in 0.1 ml Tris buffer at pH 8.5 and this solution was slowly 
added to the thyrocalcitonin solution over the course of 1 min. The 
reaction was stirred at RT under nitrogen for 18 h. The reaction was 
quenched with 10% HCI until the pH of the reaction was 2-3. The 
reaction was extracted with EtOAc to remove any unreacted OTT and 
DTU. The reaction mixture was lyophilized to a blue solid. The residue 
was purified on a 1 x20 cm column using Biogel-P (fine) (Bio-Rad) and 
0.1 M acetic acid as eluent. The Biogel-P was prepared according to 
Bio-Rad instructions. The buffer chosen for the elution was 0.1 M acetic 
acid. This buffer was chosen because of its use in a paper dealing with 
the purification of porcine thyrocalcitonin 11 o. The buffer was prepared 
according to a literature procedure 127. The fractions were eluted at a 
rate of around 5 ml/15 min. The blue band was retained at the top of the 
column. MeOH was added to the buffer in order to elute this band. This 
band was collected after eluting 10 ml of 3;2 mixture of MeOH ;water. 
The residue was concentrated down to a blue powder using high 
vacuum. UV/Vis 603 nm (£=37,895). 
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